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ABSTRACT
A core cleavage complex (CCC) consisting of CPSF73, CPSF100 and Symplekin is
required for co-transcriptional 3’ end processing of all metazoan pre-mRNAs, yet little is
known about the in vivo molecular interactions within this complex. The CCC is a
component of two distinct complexes, the cleavage/polyadenylation complex and the
complex that processes non-polyadenylated histone pre-mRNAs. RNAi-depletion of CCC
factors in Drosophila culture cells causes reduction of CCC processing activity on histone
mRNAs, resulting in read through transcription. In contrast, RNAi-depletion of factors only
required for histone mRNA processing allows use of downstream cryptic polyadenylation
signals to produce polyadenylated histone mRNAs. We used Dmel-2 tissue culture cells
stably expressing tagged CCC components to determine that amino acids 272-1080 of
Symplekin and the C-terminal ~200 amino acids of both CPSF73 and CPSF100 are required
for efficient CCC formation in vivo. Additional experiments reveal that the C-terminal 241
amino acids of CPSF100 are sufficient for histone mRNA processing indicating that the
first 524 amino acids of CPSF100 are dispensable for both CCC formation and histone
mRNA 3’ end processing. CCCs containing deletions of Symplekin lacking the first 271
amino acids resulted in a significantly increased use of downstream polyadenylation sites
for histone mRNA 3’ end processing similar to RNAi-depletion of histone specific 3’ end
processing factors FLASH, SLBP and U7 snRNA. We propose a model in which CCC
formation is mediated by CPSF73, CPSF100 and Symplekin C-termini, and the N-terminal
region of Symplekin facilitates co-transcriptional 3’ end processing of histone mRNAs.
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Chapter 1: Introduction
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Introduction
Regulation of gene expression is vital for proper cellular differentiation, cellular
proliferation, and organismal development. At the post-transcriptional level this
regulation involves multiple steps, including proper processing of pre-mRNAs. Metazoan
pre-mRNAs require extensive processing before becoming mature mRNAs, and these
processing events include 5’ end modification, splicing, and 3’-end processing. Cleavage
followed by polyadenylation is a vital processing event for all non-histone mRNAs. 3’-end
processing of canonical poly(A) pre-mRNAs involves a single endonucleolytic cleavage
event between an upstream conserved AAUAAA hexanucleotide sequence and a U- or
G/U-rich downstream element. Interestingly, maturation of histone pre-mRNAs, which
are not polyadenylated, requires only a single cleavage event between an upstream stem
loop (SL) analogous to the AAUAAA in canonical poly(A) mRNAs, and the histone
downstream element (HDE). These different cis elements are responsible for recruiting
either histone or canonical poly(A) mRNA specific processing factors. The SL in histone
mRNAs is bound by the stem loop binding protein (SLBP) while the HDE interacts with the
U7snRNA component of the U7 small nuclear ribonucleic protein particle (snRNP)
(Marzluff et al. 2008). General and histone specific 3’-end processing factors are recruited
to the histone pre-mRNA via the U7snRNP, presumably due to an interaction between
Lsm11 and FLASH (Sabath et al. 2013). The AAUAAA hexanucleotide characteristic of
canonical poly(A) mRNAs binds cleavage and polyadenylation stimulation factor 30
(CPSF30) and WDR33 (Schönemann et al. 2014). Cleavage stimulation factor 64 (CstF64)
contacts the less conserved G- or G/U rich element (Takagaki and Manley 1997). While
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both types of mRNAs use unique proteins, an essential core cleavage complex comprised
of CPSF73, CPSF100, and Symplekin is required for proper processing of all metazoan
mRNAs. CPSF73 is the enzyme responsible for catalyzing the endonucleolytic cleavage
reaction (Mandel et al. 2006), and CPSF100 forms a heterodimer with CPSF73. Symplekin
acts as a scaffolding protein onto which other cleavage and polyadenylation proteins bind
(Dominski et al. 2005; Takagaki and Manley 2000).
Poly(A) pre-mRNA 3’-end processing:

At the post-transcriptional level proper gene expression is highly regulated and
involves proper processing of pre-mRNAs. Metazoan pre-mRNAs require extensive
processing before becoming mature mRNAs that can be translated into protein via
ribosomes located in the cytoplasm. Pre-mRNA processing events include 5’-end
modification, intron splicing, and 3’-end processing. Pre-mRNA 5’-end modification
creates the 5’-cap present on all mature mRNAs. Addition of the mRNA cap occurs in the
nucleus where by a GTP molecule is attached to the first encoded nucleotide (N1) of a
transcript. The GTP molecule is attached to the first nucleotide via an unusual linkage in
which the 5ʹ hydroxyl group of the GTP is connected to the 5ʹ hydroxyl group of the
nucleotide by three phosphate groups (Gu and Lima 2005; Adams and Cory 1975). The
most well-characterized methyl group is found on the N7 position of the essential
guanosine. Methylation of N7 is required for mRNA export and subsequent recognition of
the 5’-cap by the eukaryotic translation initiation factor 4E (eIF4E)(Gu and Lima 2005). In
vitro experiments reveal that lack of this N7 methyl group significantly reduces
translational efficiency (Muthukrishnan et al. 1975).
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Pre-mRNA 3’-end cleavage followed by polyadenylation is a vital processing event
for all non-histone mRNAs. 3’-end processing of canonical poly(A) pre-mRNAs involves a
single endonucleolytic cleavage event. Cleavage occurs within the mRNA’s 3’Untranslated region (UTR) and relies on the presence of two conserved cis elements: an
upstream conserved AAUAAA hexanucleotide sequence and a U- or G/U-rich downstream
element. These cis elements bind specific protein factors that subsequently recruit
numerous protein complexes required for proper canonical poly(A) 3’-end mRNA
processing. The AAUAAA hexanucleotide characteristic of canonical poly(A) mRNAs binds
CPSF30 and WDR33 (2014; Schönemann et al. 2014). Cleavage stimulation factor 64
(CstF64) contacts the less conserved G- or G/U rich element (Takagaki and Manley 1997).
An essential core cleavage complex, here termed the CCC, is required for proper
processing of all metazoan mRNAs. This complex is comprised of three proteins: CPSF73,
CPSF100, and Symplekin. CPSF73 is the enzyme responsible for catalyzing the
endonucleolytic cleavage reaction (Mandel et al. 2006; 2004; 2005), and CPSF100 forms
a heterodimer with CPSF73. Symplekin acts as a scaffolding protein onto which other
cleavage and polyadenylation proteins bind (Dominski et al. 2005; Takagaki and Manley
2000).
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Figure 1-A: Polyadenylated mRNA 3’-end processing

Polyadenylated mRNA 3’-end
5’

(10-30 nt)

(~30 nt)

AAUAAA

U- or G/U-rich DSE

5’
5’

AAUAAA

U- or G/U-rich DSE

3’

3’

3‘-Poly(A) tail
Single Nucleotides

Polyadenylated mRNA 3’-end processing. Polyadenylated mRNAs have two
conserved cis elements: An ‘AAUAAA’ hexanucleotide sequence upstream of the
cleavage site and a U- or G/U-rich downstream element (DSE). Cleavage occurs
between these two elements. The upstream product is polyadenylated at its 3’-end
while the downstream product is degraded to single nucleotides.
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Alternative Cleavage and Polyadenylation:
The 3’-end processing machinery itself is a massive protein complex containing
over 70 loosely bound polypeptides (Shi et al. 2009). Several of these 3’-end mRNA

processing factors have been shown to regulate alternative cleavage and polyadenylation
(APA). APA is a cellular process that only recently has been recognized as an important
component of post-transcriptional gene regulation thanks to the advent of highthroughput sequencing techniques and subsequent mapping programs capable of
detecting the presence of multiple polyadenylation signals (PAS’s) within a given protein
encoding gene. This gave rise to the discovery of both the prevalence of APA and cell
specific patterns/preferences of each APA transcript (Jenal et al. 2012; Martin et al. 2012;
Yao et al. 2012).
Alteration of the coding sequence enables APA to regulate the function of the
affected genes, whereas altering the length of the 3’ UTR enables APA to affect the
stability, cellular localization, and/or translation efficiency of the target RNAs(Elkon et al.
2013). The 3’ UTR is known to be the target of regulatory factors such as microRNAs and
RNA binding proteins [13,14]. Thus altering the length of this potential regulatory region
can have a significant impact on cellular function (refer to Figure 1-C). Consider cells that
utilize proximal poly(A) sites on mRNA isoforms of the proto-oncogenes cyclin D2 (CCND2)
and insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1). These short isoforms
of the gene no longer possess let-7 and/or miR-15/16 target sites and as a result are either
more proliferative (CCND2) or oncogenic (IGF2BP1) than those transcripts expressing the
longer mRNA isoforms(Mayr and Bartel 2009). APA has also been shown to affect cellular
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localization of proteins, as can be seen in the case of brain-derived neurotropic factor
(BDNF). Proximal APA of BDNF generates a shorter mRNA isoform that is confined to the
neuronal soma while the distal APA site produces a longer isoform that is localized to the
dendrites where it is translated(An et al. 2008).
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Figure 1-B: The main Alternative Polyadenylation Patterns

Schematic illustration of the main Alternative Polyadenylation Patterns. APA can
occur at tandem 3’-UTR sites, at alternative terminal exons, at intronic sites, and at
exonic coding sequence sites (CDS). The top illustration represents the pre-mRNA
transcript and the location/presence of multiple polyadenylation sites (PAS). All
illustrations below the primary pre-mRNA transcript represent the various
patterns/locations of APA. The effects of APA are often gene specific and vary
depending on where the APA occurred. Adapted from Gruber et al (2014).
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It remains unclear how general mRNA 3’-end processing factors regulate APA of
specific transcript sets and why distinct APA patterns are seen in different mRNAs. Recent
global studies revealed that APA is dynamically regulated during development, and deregulation is associated with a number of diseases (Di Giammartino et al. 2011; Shi 2012;
Elkon et al. 2013; Mueller et al. 2013; Tian and Manley 2013). Stem cells and cancer cells
tend to favor proximal poly(A) sites (PAS), whereas differentiated or quiescent cells
generally use distal PAS (Flavell et al. 2008; Sandberg et al. 2008; Ji et al. 2009; Mayr and
Bartel 2009; Shepard et al. 2011; Elkon et al. 2012). APA regulators and 3’ end processing
factors appear to elicit effects that are cell-type specific. They affect embryonic stem cells
by regulating specific sets of mRNA transcripts, although the mechanism of this is unclear.
Fip1 has been identified as an essential 3’ end-processing factor and is a subunit
of CPSF. As such it is involved in PAS recognition and in recruiting poly(A) polymerase
(PAP) to the 3’ end processing complex(Kaufmann et al. 2004). Fip1 also regulates mRNA
alternative polyadenylation in embryonic stem cells (ESCs) as determined via direct RNA
sequencing and mapping of RNA poly(A) sites globally (Lackford et al. 2014).
The addition of poly(A) tails to mRNAs requires the aid of poly(A) binding proteins
(PABPs). These proteins are found both in the nucleus and in the cytoplasm. The poly(A)
Binding Protein Nuclear 1 (PABPN1) functions during poly(A) tail addition to mRNAs, and
in vitro studies show that PABPN1 addition to CPSF/PAP complexes strongly stimulates
the polyadenylation reaction(Kühn et al. 2009) (Wahle 1995).
A study by Jenal et al. shows that PABPN1 modulates APA via suppressing the
usage of weak proximal PASs. This is evidence that PABPN1 acts before the cleavage and
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polyadenylation of mRNAs to control the rate of proximal PAS usage(Jenal et al. 2012). It
was also found that PABPN1 knockdown (KD) induces early termination of Polymerase II
transcription. This supports the idea that reducing the level of PABPN1 results in the
activation of proximal cleavage site usage (refer to Figure 1-D) (Jenal et al. 2012). This is
the opposite of what was found for Fip1 KD, suggesting the two proteins are differentially
regulated when it comes to APA. Proximal PAS usage is not a consequence of activating
the 3’-end processing machinery globally, indicating that PABPN1 alone plays a direct role
in suppressing PAS-mediated cleavage at proximal sites(Jenal et al. 2012). Selection of the
distal PAS site due to the presence of PABPN1 then allows for the target transcript to be
regulated by its full 3’ UTR sequence(Jenal et al. 2012). In addition to enhancement of
proximal cleavage site usage, loss of PABPN1 was found to induce global 3’UTR shortening
via the use of 3’ end sequencing, and KD of PABPN1 was shown to promote usage of noncanonical proximal PASs (Jenal et al. 2012).
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Figure 1-C: PABPN1 KD Causes a shift in PAS usage

A UCSC screenshot showing the shift in PAS usage of CCND1 in PABPN1 KD cells. A
RNA-sequencing study by Jenal et al. shows that PABPN1 modulates APA via
suppressing the usage of weak proximal PAS (bottom 2 lines of the figure; top 4 lines
are controls). Thus PABPN1 must act before the cleavage and polyadenylation of
mRNAs to control the rate of proximal PAS usage. Additionally, PABPN1 KD was found
to induce early termination of Polymerase lI transcription. This supports the idea that
reducing the level of PABPN1 results in the activation of proximal cleavage site usage.
Adapted from Jenal et al. (2012)
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Human loss of PABPN1 results in a genome-wide enhancement of proximal
cleavage site usage(Jenal et al. 2012). Results from this study indicate that PABPN1
suppresses APA sites and suggests that unbalanced APA is a causal factor in
Oculopharyngeal muscular dystrophy (OPMD)(Jenal et al. 2012). This is an autosomaldominant form of late-onset slowly progressive myopathy caused by short expansions of
a (GCG)6 triplet repeat to (GCG)8-13 in the PABPN1 gene (trePABPN1) (Rüegg et al. 2005;
Brais et al. 1998). trePABPN1 causes the aggregation of nuclear proteins and formation
of filamentous nuclear inclusions, both of which are classical signs of OPMD(Calado et al.
2000). This evidence supports a role for PABPN1 in APA.
Cleavage Factor I (CFIm) is a component of the 3’ end processing apparatus and is
a tetramer composed of two 25 kDa subunits and two larger polypeptides of 59 or 68 kDa
that can be modified via methylation(Yang et al. 2011; Coseno et al. 2008; Martin et al.
2010). KD of CFIm68 induces the use of proximal PAS, as seen in Figure 1-E, mimicking the
behavior observed in proliferating stem cells(Martin et al. 2012). This also mimics the APA
pattern observed for PABPN1 KD. Preliminary A-seq data, which is a sequencing method
that enables sequencing of mRNA 3’ ends in the sense direction and avoids sequencing
through regions of As or Ts, reveals that CFIm68 KD leads to a systemic, transcriptomewide shift toward the preferential use of more proximal APA sites(Martin et al. 2012).
Cells expressing normal levels of CFIm68 tend to skip proximal cleavage sites. This begs
the question of how the distal site is preferentially chosen over the proximal site. Previous
studies suggest it is possible that stable binding of CFIm68 at the distal site is required for
proper CPSF function and 3’ end processing. Alternatively, CFIm68 could interact with
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UGUA motifs upstream of the two PASs, looping out the proximal site and making the
distal site more preferable to cleavage(Martin et al. 2012).
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Figure 1-D: CF Im68 knockdown alters poly(A) site choice based on A-seq results

Effects of CF Im68 siRNA treatment on the poly(A) site choice (genome browser panel
showing the A-seq results): KD of CFIm68 induces the use of proximal PAS, as seen in
the panel above. This mimics the behavior observed in proliferating stem cells. This
also mimics the APA pattern observed for PABPN1 KD(Figure 1-C). A-seq, a sequencing
method that enables sequencing of mRNA 3’ ends in the sense direction and avoids
sequencing through regions of As or Ts, data shows that CFIm68 KD (bottom line of the
above genome browser panel) leads to a systemic, transcriptome-wide shift in APA site
usage to the more proximal APA site. Adapted from Martin et al. (2012)
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Cleavage stimulation factor 64 (CstF64) is a part of the CstF complex and an
essential pre-mRNA processing factor. CstF64 and CstF64τ are paralogs of each other and
the two proteins have similar structural domains(Yao et al. 2012). CstF64τ has been
isolated with the CstF complex, yet its precise function remains unknown(Yao et al. 2012).
CstF64τ may suffice for CstF complex formation and function when CstF64 is
downregulated, as CstF64τ has previously been shown to be essential for
spermatogenesis when CstF64 is RNAi-depleted(Martin et al. 2012; Dass et al. 2007).
These results suggest that the two proteins have redundant functions, with CstF64τ taking
over when CstF64 is absent(Martin et al. 2012). CstF64 is thought to be a general 3’ end
processing factor, yet study results indicate that CstF64 depletion affects the APA of only
a specific subset of genes(Yao et al. 2012). However, how CstF64 regulates APA remains
unknown(Yao et al. 2012). CstF64 is known to be an important APA regulator in specific
situations such as antibody production via B-cells. CstF64 protein levels increase during
B-cell differentiation, which leads B-cells to switch from using the strong distal PAS to
using the weaker proximal PAS in the pre-mRNA. This ultimately leads to a change from
the membrane bound form of the IgM antibody to the secreted form of the
antibody(Takagaki et al. 1996; Yao et al. 2012).
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Figure 1-E: Enriched Sequence Motifs for mRNA 3’-end processing

Sequence motifs that are most enriched in the binding sites of 3’-end mRNA
processing factors. Research shows that the RNA-binding specificities of CstF64 and its
paralog CstF64τ overlap one another, as evidenced by their enriched sequence motifs
identified in Figure 1-E above. The similarity of binding sites is evidence that the two
factors play redundant roles in APA regulation. Fip1, a component of the CPSF complex
and thus a 3’-end mRNA processing factor, has an enriched sequence motif matching
that of canonical PASs. More recent data identified Fip1 as the protein factor that
directly binds the AAUAAA PAS. Adapted from Martin et al. (2012)
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Abundant levels of CstF64 promote proximal PAS usage whereas decreased CstF64
levels reduce efficiency of proximal PAS recognition, which allows the stronger more
distal PAS site to be recognized by the 3’ end processing machinery (refer to Figure 1-G.)
(Yao et al. 2012). This is similar to the APA pattern observed for Fip1 KD. Shifting the APA
pattern to distal PAS usage during stem cell differentiation and development leads to a
decrease in the mRNA levels of many core 3’ processing factors, including
CstF64/τ(Shepard et al. 2011; Ji et al. 2009; Ji and Tian 2009). iCLIP-seq and in vitro
biochemical data reveal that the strength of interaction between CstF64 and PASs on
mRNA vary greatly. Research has shown that the RNA-binding specificities of CstF64 and
its paralog CstF64τ overlap one another. Thus, the factors may play redundant roles in
APA regulation. This functional redundancy likely explains why depletion of CstF64 alone
had a minor effect on cellular growth and the APA profile compared to when both
CstF64/τ were co-depleted(Yao et al. 2012).
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Figure 1-F: KD of CstF64 results in APA Changes in six target genes

RT-q PCR data verifying APA changes in six genes. Increased levels of CSTF64
promote proximal PAS usage whereas decreased CstF64 levels reduce efficiency of
proximal PAS recognition. Thus the stronger more distal PAS site is recognized by the
3’ end processing machinery y-axis shows the log2 ratio of RNAi/HeLa (extended/
common). Adapted from Yao et al. (2012)
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Histone mRNA 3’-end Processing:

Maturation of histone pre-mRNAs, which are not polyadenylated, requires only a
single cleavage event between an upstream stem loop (SL) analogous to the AAUAAA in
canonical poly(A) mRNAs, and the histone downstream element (HDE) (Figure 1-G). The
SL in histone mRNAs is bound by the stem loop binding protein (SLBP), while the HDE
interacts with the U7 RNA component of the U7 small nuclear ribonucleic protein particle
(snRNP) (Marzluff et al. 2008). Histone mRNA processing factors are recruited to the premRNA’s 3’-end via the U7snRNP due to an interaction between Lsm11 and FLASH (Sabath
et al. 2013). While both types of mRNAs use unique proteins, an essential core cleavage
complex comprised of CPSF73, CPSF100, and Symplekin is required for proper processing
of all metazoan mRNAs (Figure 1-H). CPSF73 is the endonuclease performing the cleavage
reaction (Mandel et al. 2006), CPSF100 binds to CPF73 forming a heterodimer, and
Symplekin acts as a scaffolding protein onto which the other two proteins bind (Dominski
et al. 2005; Takagaki and Manley 2000).
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Figure 1-G: Histone pre-mRNA 3’-end processing.
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Schematic of Canonical Histone pre-RNA mRNA 3’-end Processing. Unlike canonical
poly(A) mRNAs, histone mRNAs end in a highly conserved stem loop (SL) ~5 bases
upstream of the cleavage site. 10 nucleotides downstream of the cleavage site lies
the less conserved histone downstream element (HDE). Following cleavage, the
upstream cleavage element represents the mature histone mRNA while the
downstream cleavage element is degraded to single nucleotides.
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Previous in vivo studies in Drosophila Dmel-2 cells have demonstrated that the
mRNA 3’-end processing factors Symplekin, CPSF73, and CPSF100 (here termed the Core
Cleavage Cpmplex or CCC) form a stable complex vital for proper 3’-end processing of
both histone and canonical poly(A) pre-mRNAs. RNAi-mediated knock-down of individual
CCC proteins results in co-depletion of the other two factors, indicating tight complex
formation between these proteins (Figure 1-I). In addition, knock-down of individual CCC
proteins leads to misprocessing of histone pre-mRNAs (Figures 1-J). Misprocessing of
Drosophila histone mRNAs results in one of two outcomes depending on the processing
factor involved. In the Drosophila genome, the 3’- ends of four histone genes are less than
500 nucleotides from the 3’-end of an adjacent gene transcribed from the opposite strand
(Figure 1-K). The close proximity of the histone genes on Drosophila chromosome 2 makes
it essential to efficiently terminate transcription at the proper histone processing site so
that read-through (RT) transcription does not occur into the adjacent gene. Thus, several
cryptic polyadenylation signals exist downstream of each Drosophila histone gene incase
processing efficiency of histone mRNAs is reduced (mutation or knock-down of protein
factors required for histone mRNA 3’-end processing). In such a case where histone mRNA
processing efficiency is reduced, RNA Polymerase II will read-through to the cryptic
poly(A) sites, and the mRNAs will become polyadenylated (Figures 1-J, 1-K, &1-L) (Godfrey
et al., 2006; Sullivan et al., 2001). If the proper histone processing site is not recognized
the cryptic poly(A) sites can be utilized by the poly(A) 3’-end processing machinery and
generate poly(A) histone mRNAs, but only if the poly(A) specific 3’-end processing
machinery, which includes the CCC, is intact (Figure 1-L) (Sullivan et al. 2009; Godfrey et
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al. 2006). If a poly(A) 3’-end processing factor is RNAi-depleted a read-through (RT)
transcript bypassing all cryptic poly(A) signals is generated. This is presumably due to the
inability of the poly(A) 3’-end processing machinery to recognize and cleave at the
downstream cryptic poly(A) sites (Figures 1-J & 1-L). These preliminary data highlight the
importance of the CCC in proper 3’-end processing of all metazoan pre-mRNAs.
RNA-processing reactions do not occur as individual events, but instead have been
shown to occur cotranscriptionally (reviewed in Bentley, 2005; Buratowski, 2005;
Neugebauer, 2002; Proudfoot, 2004). Several components of the poly(A) mRNA
processing apparatus directly bind the Carboxy-terminal domain (CTD) of RNA Pol II
(Kyburz et al., 2003; McCracken et al., 1997; Phatnani and Greenleaf, 2004), implying that
numerous cleavage and polyadenylation factors can be loaded onto RNA polymerase II.
Several cleavage and polyadenylation factors have been found to associate with genes
encoding mRNAs via the use of chromatin immunoprecipitation (ChIP) experiments, and
in vitro experiments have shown the CTD to be important for efficient cleavage and
polyadenylation reactions to occur (Hirose and Manley, 1998). Lastly, in vitro data shows
that Drosophila RNA Pol II pauses just 3’ of the proper histone mRNA processing site on
histone genes. This pausing potentially positions RNA Pol II in a position that allows for
cotranscriptional assembly of the processing complex (Adamson and Price, 2003).
Collectively these data support the idea that the 3’-ends of both polyadenylated and
histone mRNAs are formed cotranscriptionally.
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Figure 1-H: Schematic illustration of the 3 CCC proteins
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Schematic illustration of the Core Cleavage Complex factor proteins: Symplekin
(top), CPSF73 (middle), and CPSF100 (bottom). Biologically important protein
domains are labeled as shaded boxes within the schematic for each protein.
CPSF73 is the endonuclease that carries out the mRNA cleavage reaction, and
catalytically important residues are listed above the schematic for that protein.
Adapted from Michalski and Steiniger, (2015)
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Figure 1-I: Co-depletion of Core Cleavage Complex proteins

Co-depletion of Core Cleavage Complex factors. Target proteins were individually
depleted via RNAi, which requires the addition of dsRNA complementary to the open
reading frame (ORF) of the corresponding protein. Next Nuclear extracts (NE) were
prepared. SDS-PAGE and Western blotting was used to resolve 15ug of NE using the
indicated antibodies. “Loading control” is a cross-reacting band from the Symplekin
antibody on the blot. KD of one core cleavage complex factor via RNAi results in codepletion of the other two factors. This suggests tight complex formation between
the three protein factors. Adapted from Sullivan et al. (2009)
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Figure 1-J: KD of pre-mRNA 3’-end processing factors results in histone mRNA
misprocessing

Knockdown of pre-mRNA-processing factors results in misprocessed histone mRNA.
Dmel-2 cells were treated with target dsRNAs, and total RNA was prepared. 12.5 μg
total RNA was analyzed by S1 nuclease protection assay. Diagrams at left indicate
dsRNA species corresponding to protected fragments. Undigested probe is shown in
lane 13 for reference. Read-through transcripts (RT) are marked with an arrow.
Adapted from Sullivan et al., (2009).
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Figure 1-K: Schematic of Drosophila histone gene locus

257nt

Schematic of one repeat (~5 kb) within the Drosophila histone gene locus. The
direction of transcription is shown directly below each histone gene (H1, H2A, H2B,
H3, and H4). The number of nucleotides between each histone gene is shown above.
Adapted from Michalski and Steiniger, (2015).
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Figure 1-L: Misprocessed histone mRNAs are polyadenylated following KD of histone
specific processing factors:

Knockdown of Pre-mRNA-Processing Factors Results in Misprocessed Histone mRNA.
25ug total RNA was fractionated on oligo(dT) cellulose, and the purified poly(A)+ RNA
was used for running S1 nuclease protection assay. A small amount of processed histone
mRNA nonspecifically binds to the oligo(dT) cellulose. Adapted from Sullivan et al.
(2009).
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U7snRNA and the U7snRNP:

The U7snRNA is approximately 58–63 nucleotides long, depending on the species,
and is bound by a number of Sm and Sm-like (Lsm) proteins. These Sm and LSM proteins
are characterized by two closely spaced, conserved Sm motifs (1 and 2) (Cooper et al.
1995; Hermann et al. 1995; Séraphin 1995), and adopt a fold consisting of an α-helix
followed by five β-strands(Kambach et al. 1999). A common characteristic of Sm/Lsm
proteins is their tendency to form oligomers that can close into hepta- or hexameric ring
structures. These structures control and/or contribute to various aspects of RNA
metabolism (Pillai et al. 2001). The seven prototype Sm proteins B/B’, D1, D2, D3, E, F,
and G form the Sm core structure around the conserved Sm-binding site of the
spliceosomal small nuclear RNAs (Pillai et al. 2003). The U7snRNP contains a unique Smbinding site thought to be partially responsible for its unique Sm protein
composition(Pillai et al. 2001). The 5ʹ-end of the U7snRNA is complementary to the HDE
in histone pre-mRNAs. Base-pairing between the U7snRNA and the HDE is vital for
assembling a functional histone 3’-end processing complex (Müller and Schümperli 1997;
Dominski and Marzluff 1999). Following this base-pairing region, U7snRNAs contain a
non-canonical Sm-binding site, AAUUUGUCUAG, followed by a long hairpin structure and
a short single-stranded 3ʹ extension.
Previous in vitro and in vivo studies identified LSM10 and LSM11 as U7snRNP
specific proteins replacing the canonical Sm proteins D1 and D2 (Pillai et al. 2003). The Sm
binding site of the U7snRNA is different from that found in other spliceosomal snRNAs.
This unique feature of the U7snRNA is thought to be responsible for the relatively low
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abundance of U7snRNPs within the cell (Pillai et al. 2001). When the unique U7 Smbinding site (AAUUUGUCUAG) was converted to the consensus sequence of spliceosomal
snRNPs (AAUUUUUGGAG), the resulting snRNPs accumulated more efficiently into
transfected cells or microinjected Xenopus oocytes, yet they were non-functional in
histone mRNA 3ʹ processing (Pillai et al. 2003). This finding suggests that the unique U7
Sm-binding sequence is at least partially responsible for assembling the U7-specific snRNP
structure, whereas the canonical Sm-binding site results in standard Sm-core structures
(Pillai et al. 2001).
The “survival of motor neurons” (SMN) protein, which is a part of the SMN
complex, is a key player in Sm ring formation. This complex is composed of 18 or more
distinct proteins, including all of the Sm proteins(Meister et al. 2001; Pellizzoni et al.
2002). In vitro reconstitution of the assembly reaction revealed that Sm proteins first
associate with the SMN complex in the cytoplasm and are subsequently transferred to
the U snRNA and shuttled to the Histone Locus Body (HLB) within the nucleus (Pillai et al.
2003). Additional studies have shown that the SMN complex mediating spliceosomal U
snRNP assembly is not the same complex mediating U7snRNP assembly. A specialized
SMN complex that lacks Sm proteins D1 and D2 but contains the U7-specific proteins
Lsm10 and Lsm11 facilitates U7snRNP formation(Pillai et al. 2003).
Thus, current data suggest that assembly and subsequent function of the U7snRNP is
specified by its unique set of Sm/Lsm proteins and its unique Sm-binding site (Pillai et al.
2003). Experimental in vitro data reveals that the N-terminal portion of LSM11 contacts
FLASH (a histone specific processing factor), and that this interaction is essential for
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proper histone mRNA 3’-end formation (Figure 1-M) (Sabath et al. 2013). In vitro studies
in Drosophila reveal that the N-terminal region of LSM11 (a.a.1-78) contacts an internal
region of the histone specific processing factor FLASH (a.a.105-154), and that this
interaction is required for proper histone mRNA 3’-end formation. The same studies
suggest that the last 45 amino acids of the FLASH protein are required for efficient
localization of the U7snRNP to the HLB within the nucleus, and that amino acid residues
64-77 of FLASH interact with a yet unknown factor that is required for proper histone
mRNA processing. The first 64 amino acids of FLASH were found to be dispensable for
both U7snRNP localization to the HLB and histone mRNA 3’-end processing. In addition,
exogenous expression of HA-tagged LSM11 mutants in human 293T cells revealed that
the C-terminal region of LSM11 contains the Sm domain, which consists of the two Smbinding motifs(Pillai et al. 2003). This C-terminal region is suggested to be sufficient for
snRNP assembly in general, but also carries the specificity for preferential association with
the U7snRNA (Pillai et al. 2003). The genome of the model organism Drosophila
melanogaster possesses 100 tandem copies of a 5 kb repeat region containing a single
copy of each histone gene (H2A, H2B, H3, H4, and H1) on the long arm of chromosome 2
(Figure 1-K). This repeat region of histone genes cluster together and localizes to nuclear
structures termed histone locus bodies (HLBs), which are located in close proximity to
Cajal bodies (CBs) (Liu et al., 2006). HLBs also contain U7 snRNPs, the CCC factor Symplekin
(Wagner et al., 2007), and Mpm-2 (White et al., 2007), providing evidence for a role for
these nuclear bodies in histone mRNA biosynthesis.
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Figure 1-M: U7snRNP particle interacts with the 3’-end cis elements (HDE) of histone
pre-mRNAs

Schematic illustration of the U7snRNP particle interacting with the 3’-end cis elements
of histone pre-mRNAs. Base pairing between the 5’-end of the U7snRNA molecule and
the HDE is required for proper histone mRNA 3’-end processing. Also drawn are
additional 3’-end processing factors known to be involved in histone pre-mRNA
processing in Drosophila. Adapted from Sabath et al. (2014).
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Figure 1-N: U7snRNP interacts w/ the CCC and other Histone specific factors

Schematic illustrating potential interactions of the U7snRNP with the CCC
and other polyadenylation factors. Here Flash binding to the U7snRNP
creates a “primed” U7snRNAP capable of interacting with/recruiting the
essential CCC factors (CPSF73, CPSF100, Symplekin). This complex then
recruits other processing factors necessary for proper histone mRNA 3’-end
processing. Image Adapted from Sabath et al. (2014).

Michalski, Daniel, UMSL 46
Core Cleavage Complex: Interaction between Symplekin, CPSF73, and CPSF100 form a
tightly bound complex responsible for all pre-mRNA processing:

Cleavage and polyadenylation of all metazoan poly(A) mRNAs requires the
presence of two multiprotein complexes: the cleavage and polyadenylation specificity
factor (CPSF) complex and the cleavage stimulation factor (CstF) complex, which
recognize cis element signals upstream and downstream of the cleavage site,
respectively. CPSF is composed of at least CPSF30, CPSF73, CPSF100, and CPSF160, which
interact with one another (reviewed in Mandel et al., 2008) and with the AAUAAA
polyadenylation signal that is recognized by CPSF30 and WDR33 (Schönemann et al.
2014). Prior to 2014 CPSF160 was thought to be the protein responsible for directly
contacting the AAUAAA polyadenylation signal within the mRNA (Keller et al., 1991;
Murthy and Manley, 1995). CPSF73 and CPSF100 are similar both in sequence and
structural domain organization. CPSF73 and CPSF100 both have putative Beta-lactamase
domains, but while CPSF73 has been described as the endonuclease for both poly(A)
(Mandel et al., 2006) and histone mRNAs 3’-end processing (Dominski et al. 2005),
CPSF100 lacks the critical residues required for catalysis and thus displays no nuclease
activity (Figure 1-H). CPSF100 has been shown, however, to play an important role in the
cleavage reaction (Kolev et al., 2008). CstF64, a member of the CstF complex, binds the
downstream U-/GU-rich element required for polyadenylation (Yoshio and Manley,
1997). The CCC factor Symplekin, which was originally identified as a tight junction protein
in mammalian cells (Keon et al., 1996), and its yeast homolog, Pta1p, was initially
characterized as being essential for pre-tRNA processing (O’Connor and Peebles, 1992),
has been shown to interact with both CPSF and CstF in yeast (Preker et al., 1997; Zhao et
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al., 1999) and mammals (Takagaki and Manley, 2000; Vethantham et al., 2007). In
addition, Symplekin was defined as the heat-labile factor (Gick et al., 1987) required for
histone pre-mRNA 3’-end processing (Kolev and Steitz, 2005).
Together, CPSF73, CPSF100, and Symplekin form the so called Core Cleavage
Complex, or CCC. Details describing CPSF73, CPSF100 and Symplekin interactions are not
available as no structural data corresponding to the Core Cleavage Complex has been
published and X-ray crystal structures of individual components are limited. Each
individual core cleavage complex protein has X-ray crystal structures representing some
portion of the complete protein, but X-ray crystal structural data for complete proteins
individually or in complex with one another is missing for the core cleavage complex.
Figure 1-O reveals the crystal structure of the ~N-terminal 2/3 of both human CPSF73 and
yeast CPSF100, which includes the two major domains of each protein (beta-CASP domain
and metallo-beta-lactamase domain). Present in the human CPSF73 crystal structure is
the theoretical active site with the pair of zinc ions required for enzymatic activity. Both
crystal structures are displayed showing the alpha-helices and beta-sheets. Figure 1-P
provides a closer look at the beta-CASP domain of both proteins, while Figure 1-Q is a
stick model of the active site within CPSF73. Figure 1-R is a secondary structural view of
the N-terminal 271 a.a. of Symplekin, which were found to comprise a HEAT domain. The
alpha-helices create the convex face of the HEAT domain, while the beta-helices create
the concave face. HEAT domains are notorious protein binding sites, thus giving rise to
the notion that Symplekin is likely a scaffolding protein.
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Figure 1-O: Crystal Structures for partial proteins of CPSF73 and CPSF100

Structures of human CPSF-73 and yeast CPSF-100 (Ydh1). a, Schematic
representation of the structure of human CPSF-73. Secondary structures (b-strands
and a-helices) are labelled. The two zinc atoms in the active site are shown as grey
spheres. The sulphate ion is shown as a stick model. b, Schematic representation of
the structure of yeast CPSF-100. Zinc atoms in the CPSF-73 structure are shown for
reference. See Figure 1-H for schematic drawings of the metallo-b-lactamase domains
of CPSF73 and CPSF100. Adapted from Corey R. Mandel et at., (2006)
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Figure 1-P. The b-CASP domain of CPSF-73 and CPSF-100:

Schematic representation of the b-CASP domains of human CPSF-73 (a)
and yeast CPSF-100 (b). Secondary structures (b-strands and a-helices) are
labelled. Adapted from Corey R. Mandel et al., (2006)
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Figure 1-Q: CPSF73 Active Site

The active site of CPSF-73:Stick model representing the CPSF73 active site a) Shows
the Zinc binding site for human CPSF-73, with motifs labelled, and the bridging
hydroxide ion shown as a red sphere. Liganding interactions are indicated by thin
magenta lines, and hydrogen-bonding interactions by thin red lines. The arrow
represents the nucleophilic attack from the hydroxide ion. B) Shows the Zinc binding
site in L1 metallo-b-lactamase. Adapted from Corey R. Mandel et al., (2006).
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Figure 1-R: Symplekin Heat Domain Crystal Structure

Symplekin HEAT domain structure. (a) stereo view representation the original
experimental electron density. (b) Structural view of the HEAT domain within the Nterminal 271 a.a. of Symplekin. Alpha helices are lettered and numbered according to
classical HEAT naming; the alpha-helices create the convex face, while the beta-helices
create the concave face. The rainbow denotes the N to C progression of residues 22–
270. (c) Stick model indicating polar contacts within the loop 8 region of Symplekin. A.
Kennedy et al., (2009)
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Prior to this dissertation study, researchers investigating the role of CPSF73,
CPSF100, and Symplekin in histone and poly(A) pre-mRNA processing found that
Symplekin, CPSF73, and CPSF100 form a tightly bound complex, here termed the “Core
Cleavage Complex,” that is essential for proper cotranscriptional 3’-end pre-mRNA
processing of all metazoan mRNAs (Figures 1-I, 1-J, 1-L). The outcome of cleavage and
polyadenylation of histone and poly(A) mRNAs is known, yet many of the molecular
details regarding the protein-protein and protein-mRNA interactions that must occur for
proper 3’-end mRNA processing are unknown. Since the Core Cleavage Complex plays an
integral role in the 3’-end processing of all metazoan pre-mRNAs (2009), I feel that
determining the biologically relevant binding interactions in this complex is important, as
it will provide vital structural details in a complex vital for proper gene regulation at the
post-transcriptional level. In addition, determining the functionality of mutant CCCs will
further elucidate each factors role in histone mRNA 3’-end formation.
This current study, described in detail in this dissertation document, builds upon
the foundation set by the previous study that described the existence, role, and
importance of the core cleavage complex in the process of proper 3’-end mRNA
formation. This current study aims to both characterize the minimal regions of each core
cleavage complex factor protein required for binding to its endogenous binding partners
and thus still allow complex formation to occur, and then to subsequently examine the
functionality of mutant CCCs on histone pre-mRNA processing. The aims of this study will
further elucidate the molecular interactions between the CCC proteins and subsequently
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determine whether the minimal protein regions required for complex formation still allow
for efficient proper 3’-end mRNA processing of histone genes in Drosophila melanogaster.
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CHAPTER 2: General Methodology and Materials
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Plasmids and Oligonucleotides Used in this Study

All oligonucleotides used in this study for the amplification of Core Cleavage Complex
genes or gene regions (mutant proteins) and for sequencing are listed in Table 2-A. All
entry plasmids generated in this study for downstream applications (recombination into
destination vectors) are listed in Table 2-B. All destination plasmids generated from the
entry vector and subsequently transfected into Dmel-2 cells in this study are listed in
Table 2-C.
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Table 2-A. Oligonucleotides used in this Study (Amplification of Gene Regions and
Sequencing)
Oligo Name
Gene Region
Nucleotide Sequence (5' --> 3')
M13 Forward (-20)

Vector (pENTR/D Topo®)

GTAAAACGACGGCCAGT

M13 Reverse (-27)

Vector (pENTR/D Topo®)

CAGGAAACAGCTATGAC

PENTR CPSF73 Nterminal
PENTR CPSF73 Cterminal
73(466-684) stop F

CPSF73 (1) F

CACCATGACGCAGGCAACAGGTGAT

CPSF73 (684) R

TCAAAGAGCGGAGACTAGGGT

CPSF73 (466-684) F

CCTAGTCTCCGCTCTTTAGGGTGGGCGCGCC

73(466-684) stop R

CPSF73 (466-684) R

GGCGCGCCCACCCTAAAGAGCGGAGACTAGG

73 (1-465) stop F

CPSF73 (1-465) F

GGATCTTTATTTCCGTTAGGGTGGGCGCGCC

73 (1-465) stop R

CPSF73 (1-465) R

GGCGCGCCCACCCTAACGGAAATAAAGATCC

Symp FL + (272-1165)
stop F
Symp FL + (272-1165)
stop R
Symp (1-271) stop F

Symplekin (272-1165) F

CCGCCTGGCGAGGACTAGGGTGGGCGCGCC

Symplekin (272-1165) R

GGCGCGCCCACCCTAGTCCTCGCCAGGCGG

Symplekin (1-271) F

GGAAGCCTTTAAGCAGTAGGGTGGGCGCGCC

Symp (1-271) stop R

Symp (1-271) R

GGCGCGCCCACCCTACTGCTTAAAGGCTTCC

100 FL stop F

CPSF100 (1) F

CAGTATGCGATCGTTTAGGGTGGGCGCGCC

100 FL stop R

CPSF100 (758) R

GGCGCGCCCACCCTAAACGATCGCATACTG

100 (1-524) stop F

CPSF100 (1) F

CGTCGACAATGATGTTTAGGGTGGGCGCGCC

100 (1-524) stop R

CPSF100 (524) R

GGCGCGCCCACCCTAAACATCATTGTCGACG

100 (525-758) start F

CPSF100 (525) F

GCCGCCCCCTTCACCATGCAGTTGCTGGAGAAGCCC

100 (525-758) start R

CPSF100 (758) R

GGGCTTCTCCAGACCCTGCATGGTGAAGGGGGCGGC

T7 RNA Pol Binding
Sauce
T7 Promoter

Vector

ggtaatacgactcactataggg

Vector

TAATACGACTCACTATAGGG

T7 Terminator

Vector

GCTAGTTATTGCTCAGCGG

GFP-C

GFP

CATGGTCCTGCTGGAGTTCGTG

GFP-N

GFP

CGTCGCCGTCCAGCTCGACCAG

GFP-F

GFP dsRNA target region

ggtaatacgactcactatagggcgtaaacggccacaagttca

GFP-R

GFP dsRNA target region

ggtaatacgactcactatagggttctcgttggggtctttgct

CPSF73 dsRNA R

CPSF73 dsRNA target region

TTCTGGATGAATTCTGGTCG

CPSF73 dsRNA S

CPSF73 dsRNA target region

ATGCGTTGGCTTTAGTAGG

CPSF100 dsRNA R

CPSF100 dsRNA target region

GAAGGCTTTCGAAGGTGC

CPSF100 dsRNA S

CPSF100 dsRNA target region

TAGGGGAACATCACGTGGT

Symplekin dsRNA R

Symplekin dsRNA target region

CGAGCTAATTTCCGTTCTGC

M13 Forward (-20)

Vector (pENTR/D Topo®)

GTAAAACGACGGCCAGT

M13 Reverse (-27)

Vector (pENTR/D Topo®)

CAGGAAACAGCTATGAC

PENTR CPSF73 Nterminal
PENTR CPSF73 Cterminal

CPSF73 (1) F

CACCATGACGCAGGCAACAGGTGAT

CPSF73 (684) R

TCAAAGAGCGGAGACTAGGGT
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73(466-684) stop F

CPSF73 (466-684) F

CCTAGTCTCCGCTCTTTAGGGTGGGCGCGCC

73(466-684) stop R

CPSF73 (466-684) R

GGCGCGCCCACCCTAAAGAGCGGAGACTAGG

74 (1-465) stop F

CPSF73 (1-465) F

GGATCTTTATTTCCGTTAGGGTGGGCGCGCC

74 (1-465) stop R

CPSF73 (1-465) R

GGCGCGCCCACCCTAACGGAAATAAAGATCC

Symp FL + (272-1165)
stop F

Symplekin (272-1165) F

CCGCCTGGCGAGGACTAGGGTGGGCGCGCC
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Table 2-B. Entry plasmids containing all gene regions used in CCC binding study

Entry Plasmids
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®
pENTR/D Topo®

Description
FL-Symplekin
FL-Symplekin+RNAi-R
N-term Symplekin (1-271)
C-term Symplekin (272-1165)
C-term Symplekin (272-1080)
C-term Symplekin (272-926)
C-term Symplekin (272-758)
C-term Symplekin (272-625)
C-term Symplekin (272-525)
C-term Symplekin (272-395)
C-term Symplekin+RNAi-R (272-1165)
C-term Symplekin+RNAi-R (272-1080)
C-term Symplekin+RNAi-R (272-926)
C-term Symplekin+RNAi-R (272-758)
FL-CPSF100
FL-CPSF100+RNAi-R
N-term CPSF100 (1-524)
C-term CPSF100 (525-758)
C-term CPSF100 (525-647)
FL-CPSF73
FL-CPSF73+RNAi-R
N-term CPSF73 (1-465)
C-term CPSF73 (466-684)
C-term CPSF73 (466-552)
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Table 2-C. Destination Plasmids used for transfection of Dmel-2 cells

Destination Plasmids
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAHW
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH

*Description
FL-Symplekin
FL-Symplekin+RNAi-R
N-term Symplekin (1-271)
C-term Symplekin (272-1165)
C-term Symplekin (272-1080)
C-term Symplekin (272-926)
C-term Symplekin (272-758)
C-term Symplekin (272-625)
C-term Symplekin (272-525)
C-term Symplekin (272-395)
C-term Symplekin+RNAi-R (272-1165)
C-term Symplekin+RNAi-R (272-1080)
C-term Symplekin+RNAi-R (272-926)
C-term Symplekin+RNAi-R (272-758)
FL-CPSF100
FL-CPSF100+RNAi-R
N-term CPSF100 (1-524)
C-term CPSF100 (525-758)
C-term CPSF100 (525-647)
FL-CPSF73
FL-CPSF73+RNAi-R
N-term CPSF73 (1-465)
C-term CPSF73 (466-684)
C-term CPSF73 (466-552)
FL-Symplekin
FL-Symplekin+RNAi-R
N-term Symplekin (1-271)
C-term Symplekin (272-1165)
C-term Symplekin (272-1080)
C-term Symplekin (272-926)
C-term Symplekin (272-758)
C-term Symplekin (272-625)
C-term Symplekin (272-525)
C-term Symplekin (272-395)
C-term Symplekin+RNAi-R (272-1165)
C-term Symplekin+RNAi-R (272-1080)
C-term Symplekin+RNAi-R (272-926)
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pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
pAWH
*HW = N-term 3x HA-tag *WH = C-term 3x HA-tag

C-term Symplekin+RNAi-R (272-758)
FL-CPSF100
FL-CPSF100+RNAi-R
N-term CPSF100 (1-524)
C-term CPSF100 (525-758)
C-term CPSF100 (525-647)
FL-CPSF73
FL-CPSF73+RNAi-R
N-term CPSF73 (1-465)
C-term CPSF73 (466-684)
C-term CPSF73 (466-552)
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Development and validation of a Dmel-2 expression system to study in vivo protein
interactions in the CCC:
Gene Cloning and Plasmid Construction:

Full-length CPSF73, CPSF100 and Symplekin were PCR amplified from Drosophila
gene collection (DGC) clones (Open Biosystems) using specific primers listed in Table 2-A.
The amplified genes were directionally cloned into pENTRTM D-TOPO (Invitrogen) to
create CPSF73, CPSF100 and Symplekin::pENTRTMD-TOPO. Use of the pENTRTM D-TOPO
(Invitrogen) vector to directional insert our gene of interest required the addition of the
CACC 4 nucleotide sequence 5’ of the first nucleotide in the primer used to PCR amplify
the selected gene or gene region. Insertion reactions were transformed into chemically
competent DH5-alpha cells and plated onto LB+Kanamycin agar plates. Colonies were
selected, grown in 5mL selective media, and column mini-prepped. Proper gene insertion
was confirmed via restriction digest and Sanger sequencing. CPSF73, CPSF100 and
Symplekin::pENTRTMD-TOPO were each recombined with pAHW and pAWH destination
vectors (Drosophila Gateway vector collection, Carnegie Institution for Science) using
Clonase II (Life Technologies). Recombination reactions were transformed into chemically
competent DH5-alpha cells and plated on LB+Ampicillin agar plates. Colonies were
selected, grown in 5mL selective media, and column mini-prepped. Proper gene
recombination was confirmed via restriction digest and Sanger sequencing.
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Figure 2-A: Schematic illustration of cloning scheme from Entry to Destination Vector

Schematic illustration of the entry vector (pENTR TM/D-Topoâ) used for initial
cloning of full length and mutant CCC proteins. The entry vectors undergo a
recombination reaction via their LR recombination sites into the destination vector
(pAHW/pAWH). The destination vector adds a 3x HA-tag to either the N-terminal
(pAHW) or the C-terminal (pAWH) of the protein. Once the protein of interest has been
confirmed in the destination vector, these plasmids are transfected into Dmel-2 cells
and stably integrated into the genome under the selective pressure of Blasticidin.
Expression of tagged mutant CCC proteins was confirmed via Western blot using antiHA antibody. Stable cell lines (SCLs) were created for each mutant CCC protein and
subsequently used in downstream applications.
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Deletion Mutant Design, Synthesis, and Gateway Cloning to create Entry Vectors:

Deletion mutants for each of the three CCC proteins were cloned into pENTRTMDTOPO (Invitrogen) as described for their full-length counterparts. Each deletion mutant
was initially amplified from their corresponding pENTRTMD-TOPO full-length protein
coding gene, providing the necessary CACC to the 5’-end of the forward primer.
Successful synthesis of pENTRTMD-TOPO deletion mutants was confirmed via restriction
digest and anger sequencing.
Destination Vectors construction:

All pENTRTMD-TOPO deletion mutants were subsequently recombined into both
pAHW and pAWH destination vectors (Drosophila Gateway vector collection, Carnegie
Institution for Science) using Clonase II (Life Technologies) as described for their fulllength counterparts.

RNAi-Resistant Protein design and synthesis:

RNAi-resistant (RNAi-R) Symplekin, CPSF73, and CPSF100 were designed using an
online tool described in Schulz et al. (Schulz et al. 2009). This tool changes wobble bases
within a targeted area while also being sensitive to codon bias (specific for Drosophila
melanogaster). The ~500bp dsRNA fragment used for RNAi-induced protein knockdown
experiments targets a specific region of the gene’s ORF. Thus creation of RNAi-resistant
versions of core cleavage factor proteins involved input of this same targeting nucleotide
sequence into the online tool. The program’s output nucleotide sequence was identical
in length to the input sequence but had every 3rd base of the codon within the input
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sequence changed to the next most likely codon that still coded for the same initial amino
acid. This corresponded to ~180 nucleotides being different/changed from the initial wildtype input sequence, yet it maintained an identically coded amino acid sequence. This
new nucleotide sequence was thus resistant to the RNAi-induced gene silencing used
experimentally to achieve protein knockdown (Figure 2-B).
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Figure 2-B: Scheme for creating RNAi-Resistant Proteins

RNAi-Resistant Core Cleavage Complex factors: RNAi-Resistant protein factors were
constructed by changing the third (wobble) base of every codon within the target
region of exogenously introduced dsRNA. Codon bias for Drosophila melanogaster
was taken into account when designing the RNAi-Resistant nucleotide sequence
(Schulz et al., 2009).
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A DNA fragment corresponding to the ~500bp RNAi-target region was then
synthesized as a GeneArt® Strings™ DNA Fragment by Life Technologies (Grand Island,
NY). Each RNAi-R GeneArt String and corresponding Symplekin, CPSF73 or
CPSF100::pENTRTMD-TOPO were digested with restriction enzymes who’s sites flanked
the dsRNA targeting region and the RNAi-R fragment was substituted for the wild type
piece to create RNAi-R Symplekin, CPSF73 and CPSF100::pENTRTMD-TOPO. Ligation of the
RNAi-resistant DNA piece was performed using DNA T4 Ligase (Promega), and proper
ligationwas confirmed via restriction digest and Sanger sequencing. RNAi-R Symplekin,
CPSF73 and CPSF100::pENTRTMD-TOPO were each recombined with pAHW and pAWH
destination vectors as described above for the synthesis of each pENTRTMD-TOPO entry
vector. Proper recombination was again confirmed via restriction digest and Sanger
sequencing.

Creation of stable Drosophila Dmel-2 tissue culture lines:

Full length/mutant CCC factor::pAHW or full length/mutant CCC factor::pAWH
were transfected into Drosophila Dmel-2 cells with Effectene Transfection Reagent
(Qiagen) according to the manufacturer’s protocol. The pCoBlast vector (Invitrogen)
containing a Blasticidin resistance gene was co-transfected to enable selection of
successfully transfected cells. Cells were grown in SF-900 II SFM (Gibco) and maintained
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at 27°C under normal atmospheric conditions. 48-hours post-transfection, Blasticidin
(25ug/ml) was added to the media to select for stably transfected cells. Cells were split
and passaged into fresh selective media every 5 days to a concentration of 1 x 106/mL.
Stable transfection of each individual CCC factor was confirmed via Western Blot (WB)
with anti-HA antibody (Covance, Princeton NJ). Liquid nitrogen freezer stocks of each
stable cell line were created by growing stably transfected cells to a density of 10 x
106/mL, pelleting the cells in Microcentrifuge tubes, decanting selective growth medium,
and re-suspending the cell pellet in SF-900 SFM + 10% DMSO. Cell suspension was
transferred to a 2mL cryo-vial, placed into an ethanol immersed rack with sealed lid, and
kept in the -80 deg C freezer for a minimum of 24 hours. This procedure ensures cell
suspension cools at a rate of 1 deg C / min. 24-48 hours after being in the -80 deg C.
freezer, cryo-vials were placed into a Liquid Nitrogen storage tank for long-term storage.
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Figure 2-C: Schematic illustration of vector transfection and Stable Cell Line Creation

HA|CCC factor

pAHW

+

transfect

pA

HA-CCC factor

integrate

pC
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Dmel-2 Cell

Stable Dmel-2 Cell

Schematic illustration of the co-transfection of both the desired destination vector
(pAHW/pAWH) and the pCoBlast vector into Dmel-2 cells. The pCoBlast vector
contains a Blasticidin resistance gene, so 48-hrs post transfection Blasticidin is added
to the cell culture media to promote integration of the vectors into the Dmel-2
genome.
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RNAi, whole-cell lysate preparation, nuclear extract preparation and RNA isolation:

RNAi was performed as described (Sullivan et al. 2009). Essentially on Day 1 of the
knockdown experiment 2 x 106 Dmel-2 cells in 2mL of SF-900 SFM were plated in each
well of a 6-well tissue culture plate. dsRNA (1ug dsRNA/ 1 x 106 cells) targeting either the
ORF of a specific core cleavage complex protein or control dsRNA targeting the ORF of the
LacZ gene was ejected directly onto the cell culture within each well. The same procedure
of ejecting dsRNA onto the cell culture was repeated exactly 24-hours later (Day 2) and
48-hours later (Day3). On day 3, however, the total cell culture volume was split into 2
wells, original cell culture volume restored via the addition of SF-900 SFM, and the same
concentration of dsRNA was added to both split wells. On day 5, the cells were counted
with a Nexcelom cell counter and harvested for analysis. To make whole cell lysates for
use in downstream applications (IP and WB experiments), the appropriate number of cells
(typicaly 5 x 106 RNAi-depleted or control cells per IP/WB) were pelleted, washed twice
with 1mL 1x PBS, and were lysed with appropriate volume RIPA buffer (50mM Tris-HCL
(pH 8), 150m NaCL, 1% Nonidet P-40, 0.25% Na deoxycholate) plus 5uL 100x Halt Protease
inhibitor (Thermo Scientific). Cells were rotated at 4°C for 10 minutes to ensure complete
lysis and then centrifuged at 4°C for 15 min at 14,000 rpm to remove all cellular debris.
The supernatant was transferred to a new tube and filtered through a 1mL syringe with a
26 Gauge needle to shear the chromatin. NEs were prepared as described (Sullivan et al.
2009) from 1 x 108 cells and then flash frozen in liquid N2 and stored at -800C. Whole cell
lysates and NEs were used for immunoprecipitations (IPs) and protein expression analysis.
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Total RNA was extracted from RNAi-depleted or control cells with TRIzol Reagent
(Sigma) as described previously for use in S1 assays (Sullivan et al. 2009).

Antibodies:

Monoclonal and polyclonal HA antibodies (Cat #s MMS-101R and PRB-101C,
respectively, Covance, Princeton NJ) were used for both IP (3uL Ab/IP) and WB (1:1000).
Anti-CPSF73, anti-Symplekin and anti-CPSF100 antibodies were described previously
(Sullivan et al. 2009). For WB, antibodies were used at 1:1000. Secondary antibodies
conjugated to HRP were used at 1:5000. Pico or Fempto ECL (Bio Rad) was used for
visualizing blots via the use of X-ray radiography film.

Immunoprecipitation and S1 nuclease protection assay:

Immunoprecipitation experiments- IP of HA-tagged proteins were performed as
described (Sullivan et al. 2009). Essentially Dmel-2 whole cell lysate was rotated at 4°C for
1hr-overnight with Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology) coated
with either commercial HA-antibody for IP of exogenously expressed tagged protein or
appropriate polyclonal serum based antibody for IP of endogenous protein. Protein
bound beads were washed 4 x 1mL RIPA buffer, SDS-load dye added, and boiled at 100°C
for 5 min to denature/release IP’ed and Co-IP’ed proteins from Protein A/G PLUS-Agarose
beads. Samples were run on 10% SDS-PAGE gels, transferred to PVDF membrane, and
probed for core cleavage complex proteins with corresponding antibodies.
S1 nuclease protection assay- S1 nuclease protection assay was also performed as
described (Sullivan et al. 2009). The S1 nuclease protection assay used in this study was
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designed to assess histone pre-mRNA 3’-end processing. Specifically, a ~675 nucleotide
radiolabeled probe designed to be complementary to the 3’-UTR (~300 nucleotides) of
the Drosophila histone 2A (H2A) pre-mRNA followed by the proceeding ~350 nucleotides
downstream of the proper 3’-end cleavage site was cloned into a specific DNA vector. The
dsDNA vector was double digested with restriction enzymes so that the initial 20
nucleotides at the 5’-end of the probe (far 3’ intergenic region of H2A gene) were random
non-complementary nucleotide sequence enabling read-through transcription of the H2A
gene past the proper cleavage site and all cryptic downstream poly(A) sites could be
distinguished from the probe itself. The other dsDNA end generated via the double digest
left a 5’-overhang so the probes 3’-end would be filled in with Klenow (NEB) in a reaction
containing [α-32P] dCTP as the radionuclide, thus synthesizing a radiolabeled H2A premRNA probe. 15ug total cellular RNA was incubated with the radiolabeled H2A mRNA
probe overnight at 52°C. Hybridized RNA was then treated with S1 nuclease, degrading
single stranded RNA (ssRNA), and RNA was resuspended in 20 μL RNA loading dye
(containing both bromophenol blue and xylene cyanol) and run on a pre-electrophoresed
urea/acrylamide gel. Gel was dried and expose to phosphor screen or film overnight and
read by a Stormscanner (phosphor screen) or developed using film.
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Figure 2-D: Schematic of S1 Nuclease Protection Assay use to detect Histone mRNA
misprocessing

n
n
n

FIGURE 2-D. CCCs with Symplekin C-terminal residues can use downstream poly(A)
sites for H2A mRNA 3ʹ end processing. Above is a schematic of the histone 2A (H2A)
mRNA 3ʹ end. Cis elements required for proper processing are the stem–loop (SL) and
the histone downstream element (HDE). The appropriate cleavage site and the
properly processed H2A 3ʹ-end are marked with filled arrows. Downstream cryptic
polyadenylation signals and misprocessed products resulting from use of these signals
are labeled with open arrows. If neither the proper cleavage site nor cryptic
polyadenylation signals can be used for processing, an extended 3ʹ UTR product results
(RT). The 3ʹ-end labeled DNA S1 nuclease assay probe will hybridize to all of these
products. The 5ʹ 20 nt of the probe (zig-zag line) are vector sequence and cannot
anneal to the H2A 3ʹ-end products. Adapted from Michalski and Steiniger, (2015).
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IP Quantification and S1 assay quantification:

IP quantitation - Blots were scanned at 600 PPI and analyzed using ImageJ
software. Intensity of protein bands representing IP or co-IP were determined and
compared to the intensity of the corresponding input band (representing 5% of the
sample). The ratio of IP or co-IP intensity to input intensity was multiplied by 5 to
determine the percentage of total protein immunoprecipitated from the sample.
S1 Assay quantitation - Two independent experiments were quantitated for each
S1 experiment. Dried 6% Urea/TBE sample gels were placed on phosphoscreens
overnight. Phosphoscreens were scanned using a STORM Scanner and images were saved
as TIFF files. The TIFF files were imported into ImageJ software and subsequently
analyzed. Peak areas were determined for bands corresponding to RT, misprocessed and
properly processed H2A mRNAs. The sum total of all peaks in each lane was then
determined and the area for each peak (band) was divided by the sum total of peaks in
that lane to give a percentage. The percentages were averaged and the standard
deviation calculated for all products in each sample.
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CHAPTER 3:
In vivo characterization of the Drosophila mRNA 3ʹ end processing
core cleavage complex
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Introduction
An initial draft of the introduction presented in this section was completed by me.
Revisions were completed by myself and Dr. Steiniger.

Metazoan pre-mRNAs require extensive processing be- fore becoming mature
mRNAs. One important maturation step is 3ʹ end processing. Canonical polyadenylated
[poly(A)] pre-mRNAs are cleaved between a highly conserved AAUAAA and a less
conserved G- or G/U-rich downstream element followed by polyadenylation of the
upstream mRNA. Maturation of histone pre-mRNAs only requires a single cleavage event
between an upstream stem–loop (SL) analogous to the AAUAAA in canonical poly(A)
mRNAs, and the histone downstream element (HDE) (Dominski et al. 1999). Histone
mRNAs are not polyadenylated, ending in the SL. These different cis elements recruit
either histone or canonical poly(A) mRNA specific processing factors. The SL is bound by
the stem–loop binding protein (SLBP) while the HDE interacts with the U7 RNA
component of the U7 snRNP (Marzluff et al. 2008). The U7snRNP recruits processing
factors via an interaction between Lsm11 and FLASH (Burch et al. 2011; Sabath et al.
2013). The highly conserved AAUAAA characteristic of canonical poly(A) mRNAs binds
CPSF30 and WDR33 (Chan et al. 2014; Schönemann et al. 2014) and CstF64 contacts the
less con- served G- or G/U-rich element (Takagaki and Manley 1997). While both types of
mRNAs utilize unique proteins, cleavage and polyadenylation specificity factor (CPSF)73,
CPSF100, and Symplekin are essential for proper processing of all metazoan mRNAs
(Sullivan et al. 2009). CPSF73 is the endonuclease responsible for catalyzing the cleavage
reaction (Ryan et al. 2004; Dominski et al. 2005a; Mandel et al. 2006). CPSF100 forms a
heterodimer with CPSF73 and Symplekin acts as a scaffolding protein onto which other
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cleavage and polyadenylation proteins bind (Takagaki and Manley 2000; Dominski et al.
2005b).
Because the CCC plays an integral role in 3ʹ end processing of all metazoan premRNAs, determining biologically relevant binding interactions in this complex is
important. Details describing CPSF73, CPSF100, and Symplekin interactions are not
available as no structural data corresponding to the CCC have been published and X-ray
crystal structures of individual components are limited. The three- dimensional structure
of human CPSF73 reveals that the N- terminal 460 amino acids contain β-metallo
lactamase and β-CASP domains (Fig. 1A; Mandel et al. 2006). The interface of these two
domains form the nuclease active site (Mandel et al. 2006). The crystal structure of yeast
CPSF100 closely resembles the domain architecture of CPSF73 (Mandel et al. 2006).
CPSF100 has both a metallo-β-lactamase-like domain and a β-CASP domain, but CPSF100
active site residues are mutated such that CPSF100 does not function as a nuclease (Fig.
1A; Mandel et al. 2006). Previous experiments led to hypotheses that C-terminal
CPSF73/CPSF100 residues may be important for heterodimerization (Jenny et al. 1996).
Structures of the N-terminal 271 amino acids of Symplekin reveal seven pairs of α-helices
comprising a HEAT domain (Fig. 1A; Kennedy et al. 2009; Xiang et al. 2010). This Nterminal HEAT domain in human Symplekin mediates protein– protein interactions and
interacts directly with Ssu72, a RNA polymerase II carboxy-terminal domain (RNAPII CTD)
Ser5 phosphatase that is required for mRNA 3ʹ end processing in yeast (He et al. 2003;
Krishnamurthy et al. 2004; Xiang et al. 2010). The C-terminal 85 amino acids of the
Symplekin yeast homolog, Pta1, interact with Ysh1 (the yeast CPSF73 homo- log) in a
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directed yeast-two hybrid assay and full-length Pta1 interacts with yeast CPSF100 in an in
vitro pull-down as- say (Ghazy et al. 2009). Additionally, full-length Pta1 interacts directly
with the C-terminus of Ysh1 (Zhelkovsky et al. 2006). While the structure function
relationship has been investigated for regions of individual CCC components, molecular
de- tails for the complex are sparse.
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Figure 3-1

FIGURE 1.
Stably expressed, HA-tagged full-length CCC components interact with endogenous binding partners to form mixed
CCCs. (A) Schematic representations of Symplekin, CPSF100, and CPSF73 are shown. HEAT, metallo-β-lactomase (MβL),
and β-CASP shaded boxes indicate the location of distinct structural domains. Numbers listed within and above boxes
indicate amino acid positions. Those numbers with three letter amino acid abbreviations correspond to catalytic
residues. (B) Schematic of one repeat (∼5 kb) within the Drosophila histone gene locus. The direction of transcription is
shown directly below each histone gene (H1, H2A, H2B, H3, and H4). The number of nucleotides between each histone
gene is shown above. (C–E) Full-length HA-tagged Symplekin (C), CPSF100 (D), and CPSF73 (E) were immunoprecipitated
(IP) from whole-cell lysates with an anti-HA antibody. IPs were separated with SDS-PAGE, transferred to a membrane,
and probed with anti-HA, anti-Symplekin, anti-CPSF73, and anti-CPSF100 antibodies. Lane 1 is 5% input, lanes 2,3 are
controls where IPs were performed in the absence of antibody (beads) or with a nonspecific antibody (anti-Myc), and
lane 4 shows the experimental IP. The top panel of each WB set is the IP of HA-tagged protein while the lower panels
represent the co-IPs of CCC-binding partners.
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We define CPSF73, CPSF100, and Symplekin as the core cleavage complex (CCC).
These three proteins form a tight complex in vivo as evidenced by coimmunoprecipitation (co-IP) in stringent buffer conditions and codepletion of the other
two CCC factors when one CCC component is RNAi-depleted (Sullivan et al. 2009).
Previous investigations in Drosophila tissue culture (Dmel-2) cells of CCC function on
endogenous histone mRNAs reveal that this complex is required for proper histone 2A
(H2A) 3ʹ end processing. If a CCC component is RNAi-depleted, cleavage at the site
between the SL and the HDE is less efficient resulting in a read through (RT) H2A mRNA
with an extended 3ʹ untranslated region (UTR). (Wagner et al. 2007; Sullivan et al. 2009).
The RT product is the dominant misprocessed H2A product in these cells. RNAi-depletion
of histone-specific factors U7 snRNA, SLBP, and FLASH also result in less-efficient use of
the proper H2A processing site. But, in contrast to RNAi- depletion of CCC components,
these cells can use cryptic poly(A) signals downstream from the proper cleavage site to
process these mRNAs resulting in poly(A) histone mRNAs (Lanzotti et al. 2002; Sullivan et
al. 2009; Tatomer et al. 2014).

mRNA 3ʹ end processing by the CCC occurs

cotranscriptionally and coupling of RNA synthesis and processing is co- ordinated by
modifications in the repetitive heptad of the RNAPII CTD (Greenleaf 1993; Hsin and
Manley 2012). Direct interactions between the RNAPII CTD, CPSF and CstF have been
observed and removal of the RNAPII CTD causes inefficient mRNA 3ʹ end processing
(McCracken et al. 1997). 3ʹ end processing factor CPSF73 occupies both 5ʹ and 3ʹ ends of
candidate mammalian genes while polyadenylation factors CstF50 and CstF77
predominately occupy the 3ʹ ends (Glover-Cutter et al. 2008; Ni et al. 2008; Sullivan et al.
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2009). Additional data show that the CPSF complex is recruited to the 5ʹ end by TFIID and
remains associated with RNAPII throughout transcription elongation (Dantonel et al.
1997). Recruitment of mRNA 3ʹ end processing factors to the RNAPII CTD correlates with
specific phosphorylation of CTD heptad repeat positions Ser5 and Ser2. In Drosophila
tissue culture cells, impairment of Ser2 phosphorylation results in less-efficient
recruitment of mRNA 3ʹ end processing factors to the 3ʹ ends of genes (Ni et al. 2008).
Finally, the N- terminal 271 amino acids of human Symplekin interact with Ssu72, a RNAPII
CTD Ser5 phosphatase that is required for mRNA 3ʹ end processing in yeast (He et al. 2003;
Krishnamurthy et al. 2004; Xiang et al. 2010). Taken together, these data support a model
in which mRNA 3ʹ end processing is cotranscriptional.
Previous work indicates that histone pre-mRNA 3ʹ end processing is also
cotranscriptional. In Drosophila, the his- tone gene locus consists of 100 tandem repeats
of a 5-kb region containing a single copy of each replication-dependent histone gene
separated by <500 nt (Fig. 1B). Each alternating gene is transcribed from the opposite
strand, requiring coordinated transcription termination and 3ʹ end processing to prevent
transcription into neighboring genes (Sullivan et al. 2009). Evidence supporting this model
is observed in histone mRNA 3ʹ end sequences obtained from the modENCODE project
(Celniker et al. 2009). Sequencing reads are not observed downstream from the histone
3ʹ SL and cleavage site. Additionally, RNAPII pause sites downstream from the histone
mRNA 3ʹ end cleavage site have been identified that affect histone mRNA processing
(Adamson and Price 2003) and CCC components Symplekin and CPSF73 ChIP to histone 3ʹ
ends (Sullivan et al. 2009). Finally, phosphorylation of RNAPII CTD heptad residue Thr4 is
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specifically required for histone mRNA 3ʹ end processing. SLBP and CPSF100 are not
recruited to histone genes if Thr4 is not phosphorylated (Hsin et al. 2011). Collectively,
these data support a model in which pre-mRNA 3ʹ end processing, transcription and
termination are tightly coordinated.
Recent X-ray crystallographic investigations of CPSF73, CPSF100, and Symplekin
have focused on individual components and have resulted in only partial structures
(Mandel et al. 2006; Kennedy et al. 2009; Xiang et al. 2010). Additionally, previous
analyses of CCC component binding interactions are incomplete concentrating on only
two of the three factors or were performed in vitro or using bioinformatics (Jenny et al.
1996; Kyburz et al. 2003; Dominski et al. 2005b; Zhelkovsky et al. 2006). To further define
CPSF73, CPSF100, and Symplekin binding interactions, we developed a novel Drosophila
cell culture system in which tagged, mutant components were individually expressed.
Interaction of these exogenous factors with endogenous-binding partners identified
important binding regions of CPSF73, CPSF100, and Symplekin in vivo. Furthermore, the
activity of mutant component containing CCCs was assessed on an endogenous histone
mRNA to demonstrate domains important for cotranscriptional histone mRNA 3ʹ end
processing.
Results

All the experiments presented in this section (including the experimental designs and
experimental approaches) were completed by me. An initial draft of the “Results” section
was completed by me. Revisions to the writing were completed by myself and Dr.
Steiniger.
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Development and validation of a Dmel-2 expression system to study in vivo protein
interactions in the CCC

Our goal was to understand CCC interactions in vivo. Therefore, we needed to
develop a system to express tagged CCC components that could both integrate into
complexes

with

endogenous-binding

partners

(form

mixed

CCCs)

and

be

immunoprecipitated (IPed). To accomplish this goal, full-length, wild-type CPSF73,
CPSF100, and Symplekin sequences were first cloned downstream from a constitutive
promoter in plasmids conferring either an N- or C-terminal HA tag. These plasmids were
then transfected into Dmel-2 cells and maintained under selection to create polyclonal
Dmel-2 cells stably expressing CCC factors. Stable expression of CCC factors did not affect
the viability of Dmel-2 cells. Extracts used for IP were prepared from these cells and antiHA Western blot (WB) confirmed expression of full- length HA-tagged CCC proteins (Fig.
1C–E, lane 1 or Fig. 2B). To validate that stably expressed CCC factors could be IPed and
form mixed CCCs, each CCC component was individually IPed from Dmel-2 stable cell line
whole-cell lysates followed by WB for co-IP of endogenous-binding partners. IP of HAtagged Symplekin successfully co-IPed endogenous CPSF73 and CPSF100 (Fig. 1C). IP of
HA-tagged CPSF100 co-IPed endogenous Symplekin and CPSF73 (Fig. 1D). IP of HA-tagged
CPSF73 co-IPed endogenous Symplekin and CPSF100 (Fig. 1E). In each case, significant
amounts of endogenous-binding partners were observed (Fig. 3B,D,F). No IP of exogenous
factors or co-IP of endogenous proteins was observed in no (Beads) or nonspecific (αMyc) antibody controls (Fig. 1C–E, lanes 2,3). These data indicate that HA- tagged CCC
components can be stably expressed in Dmel-2 cells without affecting cell viability. Also,
the HA fusion does not prevent CCC factor expression or CCC formation with endogenous-
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binding partners. RNAi- depletion of endogenous CCC factors is not required to assess
interactions within the CCC.
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Figure 3-2

FIGURE 2. HA-tagged deletion mutants of Symplekin, CPSF100, and CPSF73 can be stably ex- pressed in Dmel-2 cells.
(A) Schematics of Symplekin (top), CPSF100 (middle), and CPSF73 (bot- tom) deletion mutants used for in vivo binding
assays are shown below each full-length protein. Each mutant is defined by the amino acids contained within the
deletion, for example (1–271). The C-terminal amino acid of each mutant is written above the full-length CCC factor.
The nucleotides targeted by dsRNA are defined by a solid rectangle. (B) HA-tagged full length (lanes 2,7,12) and N- and
C-terminally truncated CPSF73 (lanes 3–5), CPSF100 (lanes 8–10), and Symplekin (lanes 13–18) deletion mutants were
stably expressed in Dmel-2 cells. Whole-cell lysates from these strains were separated with SDS-PAGE, transferred to a
membrane, and probed with an anti-HA antibody to confirm expression. Amino acids comprising the deletion mutant
are shown following the protein name above the WB. Molecular weight (MW) markers for lanes 1–14 are on the left.
MW markers for lanes 15–18 are on the right.
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Symplekin amino acids 927–1080, CPSF100 amino acids 648–756, and CPSF73 amino acids
552–684 are required for CCC formation

IP of mixed CCCs from Dmel-2 whole- cell lysates confirms that CCCs having both
exogenous and endogenous components can be formed and isolated. Our next goal was
to determine which regions of CPSF73, CPSF100, and Symplekin are required for CCC
formation. To address this, we constructed N- and C- terminal CPSF73, CPSF100, and
Symplekin mutants. Deletion positions were determined using Phyre2 prediction software (Kelley and Sternberg 2009) and were only made in disordered regions (Fig. 2A).
Symplekin mutants were amino acids 1–271 (N-terminal), 272–1165 (C-terminal), 272–
1080, 272–926, 272– 756, and 272–625. CPSF100 mutants were amino acids 1–524 (Nterminal), 525–756 (C-terminal), and 525–647. CPSF73 mutants were amino acids 1– 465
(N-terminal), 466–684 (C-terminal), and 466–552. These mutants were constructed,
transfected, and stably expressed as their full-length counterparts in Dmel-2 cells.
Expression was confirmed in whole-cell lysates with an anti-HA WB (Fig. 2B). All mutants
IP with an α-HA antibody were detected by WB with an α-HA antibody (Fig. 3A,C,E, top
WB).
The large C-terminal HA-tagged Symplekin mutant (Symp(272–1165)) binds both
CPSF73 and CPSF100, while the N-terminal mutant (Symp(1–271)) binds neither protein
(Fig. 3A, lanes 6,8, 3B). Symp(272–1165) IPs more CPSF73 than full-length Symplekin (Fig.
3B). Increasing deletion of C-terminal resi- dues from Symp(272–1165) results in
progressively less-efficient CCC formation (Fig. 3B). Symp(272–1080) co-IPs CPSF73
comparable with full-length Symplekin (Fig. 3B). Symp(272–926) and Symp(272–758) also
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bind CPSF73 and CPSF100, but to a lesser extent than full-length Symplekin(Fig.3B).
Symp(272– 625) does not co-IP CPSF73 or CPSF100 (Fig. 3B). Two additional Symplekin
mutants, Symp(272–525) and Symp(272– 395), having even fewer C-terminal residues
also did not co-IP endogenous CPSF73 or CPSF100 (data not shown). These data indicate
that the first 271 amino acids of Symplekin are not required for CCC formation. Symplekin
aminoacids272–1080 are sufficient for CCC formation while amino acids 927–1080 are
essential for interaction with CPSF73/CPSF100.
IP of HA-tagged C-terminal CPSF100 (100(525–756)) also resulted in co-IP of
endogenous CCC-binding partners (Fig. 3C,D); 100(525–756) binds CPSF73 and Symplekin
comparable with full-length CPSF100 (Fig. 3D), while N-terminal 100(1–524) does not coIP CCC-binding partners (Fig. 3D). Deletion of an additional 109 amino acids from the Cterminus of the CPSF100 C-terminal mutant (100 (525–647)) abolishes co-IP of CPSF73
and Symplekin (Fig. 3D). These data indicate that amino acids 525–756 of CPSF100 are
sufficient for CCC formation and amino acids 1–524 are dispensable for interaction with
CPSF73 and Symplekin. CPSF100 amino acids 648–756 are required for CCC formation.
IP of HA-tagged C-terminal CPSF73 (73(466–684)) co- IPed Symplekin and CPSF100
comparable with full-length CPSF73 (Fig. 3E,F), while the N-terminal CPSF73 mutant
(73(1–465)) cannot participate in CCC formation (Fig. 3F). Deletion of an additional 133
amino acids from the C-terminus of the C-terminal CPSF73 mutant (73(466–552)) prevents Symplekin binding, but interaction with CPSF100 is maintained (Fig. 3F). These data
indicate that CPSF73 amino acids 466–684 are sufficient for interaction with CPSF100 and
Symplekin while amino acids 1–465 cannot facilitate CCC formation. Amino acids 553–
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684 are essential for binding Symplekin while CPSF100 may interact with CPSF73 amino
acids 466–552.
To ensure that phenotypes observed for mutant CCCs are attributable to the
mutant CCC component, we investigated inclusion of corresponding full-length
endogenous CCC components in CCCs having HA-tagged full-length and mutant factors.
CCCs including full-length HA-tagged proteins do not also contain endogenous CCC factors
(Fig. 3A,C,E, bottom WB, lanes 1–4). While CCC antibodies react with both endogenous
and exogenous CCC factors, the full-length HA-tagged protein in each IP is slightly larger
than the corresponding band in the input indicating that the HA-tagged protein
dominates in the IP (Fig. 3A,C,E, bottom WB, cf. lanes 1,4). The HA-tagged protein is
expressed at less than endogenous levels and therefore is not visible in the input (Fig.
3A,C,E, bottom WB, lane 1). All HA-tagged deletion mutants differ significantly in size from
their full-length counterparts allowing detection of full-length endogenous CCC
components in CCC IPs. None of the mixed complexes contain the corresponding
endogenous-binding partners (Fig. 3A,C,E, bottom WB).
Together, these data support a model in which one Symplekin, one CPSF73, and
one CPSF100 interact to form the CCC. Generally, the C-termini of each protein mediate
CCC formation. Specifically, amino acids 272–1080 of Symplekin, amino acids 466–684 of
CPSF73, and amino ac- ids 525–756 of CPSF100 are sufficient for binding, while Symplekin
amino acids 927–1080, CPSF100 amino acids 648–756 and CPSF73 amino acids 552–684
are required for CCC formation (Fig. 3G). CPSF73 amino acids 466–552 may contact
CPSF100 while CPSF73 C-terminal residues 553–684 are essential for binding Symplekin.
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Figure 3-3

FIGURE 3. Symplekin amino acids 272–1080, CPSF100 amino acids 525–756, and CPSF73 amino acids 465–684 are
sufficient for CCC formation. (A,C,E) HA-tagged Symplekin mutants (A), HA-tagged CPSF100 mutants (C), and HA-tagged
CPSF73 mutants (E) were IPed, separated, and probed with HA- and CCC-specific antibodies. Numbers under the protein
name correspond to the amino acid residues comprising each mutant. IP of full- length proteins and controls (lanes 1–
4) are included for reference. (B,D,F ) Percentage of IP or co-IPed proteins corresponding to WBs in A, C, and E are
plotted. Black bars are percent HA IP, gray bars are percent CPSF73 IP, bars with diagonal lines are percent CPSF100 IP,
and bars with black diamonds are percent Symplekin IP. In (B), the numbers above the bars correspond to percent IP
for that sample. (G) A CCC-binding model is shown. The C-termini of Symplekin, CPSF73, and CPSF100 are sufficient for
CCC formation.
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HA RNAi-resistant CCC factors express simultaneously with RNAi-depletion of endogenous
proteins and behave as wild-type CCC components

After elucidating binding interactions in the CCC, we wanted to investigate in vivo
activity of mutant CCCs. While previous experiments with HA-tagged CPSF73, CPSF100, or
Symplekin containing CCCs were performed in the presence of endogenous complexes,
functional wild-type CCCs mask in vivo activity of mutant CCCs. To focus on only mixed
CCCs, we RNAi-depleted endogenous CCC components while expressing RNAi-resistant
(RNAi-R) CCC factors. While this powerful technique has been utilized before (Ruepp et
al. 2011; Chen et al. 2013), it is a novel way to study CCC function. RNAi-R mRNAs were
constructed by introducing silent mutations at the wobble base of each codon in the
RNAi-targeted region (Fig. 4A; Schulz et al. 2009).
Stable lines expressing HA-tagged full-length R-Symplekin, R-CPSF73, and RCPSF100 were RNAi-depleted of the corresponding endogenous proteins. Symplekin,
CPSF73, and CPSF100 are efficiently RNAi-depleted when compared with either no
double-stranded or nonspecific RNA (LacZ) controls (Fig. 4B–D, top panels, lanes 1–3).
WBs with an anti-HA antibody show that RNAi-R CCC components are successfully
expressed in the presence of RNAi targeting the corresponding CCC factors (Fig. 4B–D,
bottom panels, lane 6). Concurrent expression of HA-tagged proteins and RNAi-depletion
is best observed for CPSF73; endogenous CPSF73 is clearly RNAi-depleted while the
slightly larger HA-tagged, R-CPSF73 is expressed (Fig. 4D, lanes 4–6). This phenomenon is
also observed for Symplekin, although HA-tagged Symplekin is less of the total Symplekin
pool as assessed by comparing the amount of HA-tagged and endogenous Symplekin in
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lane 6 (Fig. 4B, lanes 4–6). HA-tagged and endogenous CPSF100 are not resolved, but
reduced CPSF100 levels indicate RNAi-depletion of endogenous protein with concurrent
expression of HA-tagged CPSF100 (Fig. 4C, lanes 4–6). These experiments were repeated
for each HA-tagged CCC factor mutant to ensure that RNAi-R proteins were successfully
expressed simultaneously with RNAi-depletion of endogenous CCC components
(Supplemental Fig. 1). Finally, RNAi-R CCC factors IP endogenous-binding partners much
like their wild-type counter- parts as compared with no and nonspecific antibody controls
(Fig. 4E–G).
The C-terminal 232 amino acids of CPSF100 are sufficient for the formation of functional
CCCs

To investigate in vivo activity of mutant CCC complexes, we visualized histone H2A
3ʹ ends using an S1 nuclease assay. In Drosophila, the 3ʹ ends of replication-dependent
histone mRNAs are properly processed with a single cleavage between a conserved stem–
loop (SL) and the histone downstream element (HDE) (Fig. 5A, filled arrow). Misprocessing
of H2A occurs when downstream cryptic polyadenylation signals recruit 3ʹ end processing
factors resulting in polyadenylated H2A mRNAs (Fig. 5A, open arrows). When CPSF73,
CPSF100, or Symplekin are RNAi-depleted, neither the SL/HDE nor the cryptic
polyadenylation signals can be utilized for histone mRNA processing, resulting in an
extended 3ʹ UTR or read through (RT) product (Fig. 5A). These processed H2A mRNAs are
clearly observed following hybridization with a radioactively labeled probe and S1
nuclease digestion (Fig. 5A, probe). This assay has been used previously to investigate H2A
3ʹ end processing (Lanzotti et al. 2002; Sullivan et al. 2009). We performed each S1
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nuclease assay in duplicate followed by quantitation of the amount of properly processed,
3ʹ end misprocessed and RT H2A mRNAs. Averages of percent nonproperly processed H2A
mRNAs are included.
RNAi-depletion of CPSF100 causes H2A misprocessing when compared with
negative controls (Fig. 5B, cf. lanes 2,3 to lane 4). RT mRNA is 21.6% of total H2A mRNA
in this sample and is the primary misprocessed product (Fig. 5E). Previous experiments
are consistent with this result (Sullivan et al. 2009). When R-CPSF100 is expressed
simultaneously with RNAi-depletion of endogenous CPSF100, the amount of RT is 9.3%
(Fig. 5B,E). Expression of R-CPSF100 partially rescues the RNAi-depletion defect showing
that mixed CCC are functional. Expression of CPSF100(525–756) results in 11.6% RT H2A
misprocessing product indicating this mutant also rescues the effect of CPSF100 RNAidepletion (Fig. 5B,E). Expression of CPSF100(525–647) does not rescue CPSF100 RNAidepletion as indicated by RT levels (20.5%) comparable with the CPSF100 RNAi sample
(Fig. 5B,E). Double-stranded RNA for RNAi targets the N-terminal region of full-length
CPSF100 (Fig. 2A), therefore, RNA-R forms of CPSF100 (525–756) and CPSF100(525–647)
did not have to be constructed. Collectively, these data indicate that CCCs containing the
minimal region of CPSF100 required for CCC formation are functional and that the first
524 amino acids of CPSF100 are dispensable for proper H2A processing.
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Figure 3-4

FIGURE 4. RNAi-resistant (RNAi-R) CCC factors are expressed during simultaneous RNAi-depletion of corresponding
endogenous proteins and form complexes with endogenous-binding partners. (A) RNAi-R CCC components were
constructed by changing the third (wobble) base of every codon within the region targeted by exogenously introduced
dsRNA. (B–D) HA-tagged R-Symplekin (B), R-CPSF100 (C), and R-CPSF73 (D) were expressed in Dmel-2 cells
simultaneously RNAi-depleted of the corresponding endogenous protein. The proteins were IPed, separated, and
probed as described in Figure 1. Lane 3 of each top panel shows RNAi-depletion of endogenous CCC components.
Simultaneous RNAi-depletion of endogenous CCC factors and exogenous expression of the corresponding protein is
shown in lane 6. The “∗ ” denotes a slightly faster migrating cross-reacting band. The “#” identifies HA-CPSF73. (E–G)
RNAi-R full-length CCCs were IPed as described in Figure 1. R-Symplekin (E), R-CPSF100 (F), and R-CPSF73 (G) IP were
detected with anti-HA antibody (lane 4, top panels). co-IP was assessed with anti-CCC factor antibodies. Beads only
(lane 2) and α-Myc (lane 3) are nonspecific controls.
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Figure 3-5

FIGURE 5. CCCs with Symplekin C-terminal residues can use downstream poly(A) sites for H2A mRNA 3ʹ end processing.
(A) A schematic of the histone 2A (H2A) mRNA 3ʹ end is shown. Cis elements required for proper processing are the
stem–loop (SL) and the histone downstream element (HDE). The appropriate cleavage site and the properly processed
H2A 3ʹ end are marked with filled arrows. Downstream cryptic polyadenylation signals and misprocessed products
resulting from use of these signals are labeled with open arrows. If neither the proper cleavage site nor cryptic
polyadenylation signals can be used for processing, an extended 3ʹ UTR product results (RT). The 3ʹ end labeled DNA S1
nuclease assay probe will hybridize to all of these products. The 5ʹ 20 nt of the probe (zig-zag line) cannot anneal to the
H2A 3ʹ end products. (B) H2A 3ʹ ends in Dmel-2 cells containing wild-type and mutant CPSF100 CCCs and control cells
were visualized using a S1 nuclease assay. Addition of dsRNA is indicated just above the gel while expression of either
full-length or mutant CCC components is described above the solid line. Gel positions of potential products are marked
on the left with the same labeling as in (A). (C ) H2A 3ʹ ends in Dmel-2 cells containing wild-type and mutant CPSF73
CCCs and control cells were visualized using a S1 nuclease assay. The gel is labeled as in (B). (D) An S1 nuclease assay
was performed to visualize endogenous H2A mRNA 3ʹ ends in Dmel-2 cells with Symplekin mutant CCCs. The gel is
labeled as in (B). (E) The percentages of RT, misprocessed, and properly processed H2A mRNAs were calculated for two
independent experiments. The averages of RT and misprocessed products for each experiment were plotted with the
corresponding standard deviation and the values are indicated below each gel. The black bars are the percent of RT
product while the gray bars represent percent misprocessed H2A mRNA.
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CCCs with the C-terminal 218 amino acids of CPSF73 misprocess histone mRNAs

To investigate the in vivo activity of CCC containing CPSF73 deletion mutants, a
similar approach was used. An S1 nuclease protection assay using a probe to H2A (Fig. 5A)
shows properly processed H2A mRNA in wild-type Dmel-2 cells and controls treated with
nontargeting dsRNA (Fig. 5C, lanes 2,3). When CPSF73 is RNAi-depleted, RT mRNA is
15.0% of the total H2A product (Fig. 5C,E). Few products resulting from use of
downstream cryptic poly(A) signals were observed (5.6%). These data are consistent with
previously published findings (Sullivan et al. 2009). When full-length R- CPSF73 is
expressed simultaneously with RNAi-depletion of endogenous CPSF73, the H2A 3ʹ end
processing defect is partially rescued as only 3.0% of RT H2A is present in this sample (Fig.
5C,E). Therefore, mixed CCC with full-length R-CPSF73 are functional. When CPSF73(466–
684) is ex- pressed, 13.3% RT H2A misprocessing is observed (Fig. 5C,E). Although this
mutant forms CCCs (Fig. 3E), CPSF73(466–684) does not rescue H2A misprocessing,
presumably because it does not contain the CPSF73 active site (Fig. 2A). RT H2A
misprocessed 3ʹ ends also dominate in samples where CPSF73(466–552) is expressed
(17.2% of H2A) (Fig. 5C,E), indicating that this mutant does not rescue H2A misprocessing.
Neither CPSF73(466–684) nor CPSF73(466– 552) act dominantly as cells concurrently
expressing a mutant and wild-type full-length endogenous CPSF73 do not result in H2A
misprocessing (Supplemental Fig. 2B). As the dsRNA used for RNAi-depletion of CPSF73
targets the N-terminal region (Fig. 2A), RNAi-R forms of CPSF73(466–684) and
CPSF73(466–552) did not need to be constructed. Collectively, these data indicate that
although CPSF73(466– 684) can form CCCs, these CCCs are nonfunctional.

Michalski, Daniel, UMSL101
CCCs containing Symplekin lacking the first 271 amino acids use downstream cryptic
poly(A) sites for H2A 3’ end processing

We also investigated the activity of mutant Symplekin CCCs by visualizing the 3ʹ
ends of H2A mRNAs in Dmel-2 cells containing these complexes (Fig. 5D). RNAi-depletion
of Symplekin causes H2A misprocessing when compared with negative controls (Fig. 5D,
cf. lane 4 to lanes 2,3). RT H2A mRNA is the primary misprocessed H2A product (13.7% of
total H2A mRNA) as has been observed previously (Sullivan et al. 2009). When RSymplekin is expressed simultaneously with RNAi-depletion of endogenous Symplekin, RT
H2A mRNA is 2.8% of total H2A (Fig. 5D,E) indicating that exogenous Symplekin can
partially rescue the defect caused by RNAi-depletion of endogenous Symplekin. As with
CCCs including R-CPSF73 and R-CPSF100, R-Symplekin containing CCCs are functional.
When Symp(272–1165) is expressed in cells lacking endogenous Symplekin, misprocessed
H2A dramatically increases to 31.7% and use of cryptic poly(A) signals is abundant (Fig.
5D,E). We continue to observe this pattern as residues are progressively removed from
the Symplekin C- terminus, although the total amount of misprocessed H2A decreases;
17.8% of H2A mRNAs are misprocessed by Symp(272–1080) containing CCCs, 17.4% of
H2A mRNAs are mis- processed by Symp(272–926) containing CCCs, and 7.7% of H2A
mRNAs are misprocessed by Symp(272–758) (Fig. 5D, E). When Symp(1–271) is expressed
in cells RNAi-depleted of endogenous Symplekin, RT H2A mRNA is again the primary
misprocessing product (10.0% of total H2A mRNAs) (Fig. 5D,E). None of the Symplekin
mutants act dominantly as cells concurrently expressing a mutant and wild-type fulllength endogenous Symplekin do not result in H2A misprocessing (Supplemental Fig. 2A).
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These data indicate that 3ʹ end misprocessed H2A mRNAs are the dominant
misprocessed product in samples having CCCs with only Symplekin C-terminal amino
acids. These complexes can use downstream poly(A) signals for 3ʹ end processing of H2A
mRNAs. This is a novel result as only read through transcription has been observed when
full- length CCC components are RNAi-depleted or with non- functional CCCs.

DISCUSSION

The central ideas of the discussion and future directions presented in this section were
primarily derived by me. The most important aspect of this paper (the idea that the Nterminal 271-amino acids of Symplekin are likely responsible for the co-transcriptional 3’end processing of all metazoan pre-mRNAs while the C-terminal portion clearly binds
CPSF73 and CPSF100) was my interpretation of the data generated and presented here.
In this section Write-up of this idea and other novel insights from personal interpretation
of the experimental data presented in this section was a combined effort between myself
and Dr. Steiniger.
Pre-mRNA 3ʹ end processing is an essential step in mRNA maturation. The 3ʹ ends
of all metazoan mRNAs are cleaved by the core cleavage complex (CCC) consisting of
CPSF73, CPSF100, and Symplekin (Sullivan et al. 2009). Interactions in this important
complex have not been investigated. Furthermore, relationships between protein
domains in the CCC and their function in cotranscriptional histone mRNA 3ʹ end
processing have not been characterized. Here, we use a Dmel-2 tissue culture system to
determine that the C- terminal ∼200 amino acids of CPSF73 and CPSF100 and amino acids
272–1080 of Symplekin are sufficient for CCC formation. Additionally, in vivo assessment
of mutant CCC activity reveals that the N-terminal 524 amino acids of CPSF100 are not
required for formation of CCCs that properly process histone mRNAs. Lastly, CCCs
containing Symplekin lacking the first 271 amino acids can use poly (A) signals
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downstream from the proper cleavage site for 3ʹ end processing. This is a phenotype also
observed when his- tone-specific processing factors are RNAi-depleted but in contrast to
the read through product normally produced when CCC components are knocked down.
These data support a model in which the first 271 amino acids of Symplekin facilitate
cotranscriptional 3ʹ end processing of histone mRNAs.
A novel in vivo approach to study CCC interactions and activity

We took a novel in vivo approach to investigate both CCC interactions and mutant
CCC histone mRNA 3ʹ end processing. To identify important CCC component binding
regions, tagged mutant CCC components were first stably ex- pressed in Dmel-2 cells.
These proteins were then immuno- precipitated and co-IP of endogenous CCC-binding
partners was identified. This approach was validated using full-length, wild-type tagged
CCC factors for IP and ensuring co-IP of endogenous CCC components (Fig. 1C–E). Unlike
previous investigations of interactions within multiprotein complexes involved in RNA
processing, mixed CCCs having both exogenous and endogenous components did not
require RNAi- depletion of endogenous factors (Chen et al. 2013; Lyons et al. 2014).
Analysis of mutant CCC activity in this system necessitated an additional
modification. Previous data indicate that misprocessed histone mRNAs are a small
percentage of total histone mRNA in Dmel-2 cells RNAi-depleted of CCC components
(Sullivan et al. 2009). Therefore, we hypothesized that misprocessed histone mRNA
resulting from mutant CCC activity in our system would not be detected in the presence
of functional wild-type CCCs. To alleviate this problem, we constructed and stably
expressed RNAi-resistant CCC mutants simultaneously with RNAi-depletion of the
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corresponding endogenous CCC component (Fig. 4). This approach ensured we were only
observing activity of CCCs containing mutant factors. The activity of these complexes was
then assessed on H2A 3ʹ ends. Expression of tagged full-length, wild-type CCC
components rescued histone mRNA 3ʹ end processing when the corresponding
endogenous component was RNAi-depleted indicating that mixed CCCs are also
functional (Fig. 5). This novel Dmel-2 cell culture system could be used to further
investigate interactions in the CCC using CPSF73, CPSF100, and Symplekin point mutants.
Other factors required for cotranscriptional histone mRNA 3ʹ end processing could also
be studied using this approach.
The C-termini of CPSF73, CPSF100, and Symplekin are sufficient for CCC formation

Previous to this study, little was known about CCC interactions in vivo. The threedimensional structures of the first ∼400 amino acids of human CPSF73 and yeast CPSF100
(Mandel et al. 2006) and the N-terminal ∼300 amino acids of Drosophila and human
Symplekin were individually deter- mined by X-ray crystallography (Kennedy et al. 2009;
Xiang et al. 2010, 2012). These structures include important resi- dues comprising the
CPSF73 active site (Fig. 2) and a N- terminal Symplekin HEAT domain interacting with the
RNAPII CTD phosphatase Ssu72, but do not incorporate C-terminal CPSF73, CPSF100, and
Symplekin regions important for CCC formation. Additionally, previous bioinformatics,
yeast-two hybrid and pull-down analyses have led to hypotheses that the C-termini of
CPSF100, CPSF73, and Symplekin interact (Jenny et al. 1996; Kyburz et al. 2003; Dominski
et al. 2005b; Zhelkovsky et al. 2006; Mandel et al. 2008; Ghazy et al. 2009), but these
studies never included all three CCC components, instead focusing on only two factors.
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The experiments described here are the first systematic, in vivo approach to defining
simultaneous CPSF73, CPSF100, and Symplekin binding interactions in the CCC. We
provide evidence that amino acids 272–1080 of Symplekin, amino acids 466–684 of
CPSF73 and amino acids 525– 756 of CPSF100 are sufficient for CCC formation.
While our data are generally consistent with previous hypotheses and
observations, our experiments reveal the following novel insights. Symplekin amino acids
272–1165 co- IP more CPSF73 than full-length Symplekin, yet removing 85 additional Cterminal amino acids (Symp(272–1080)) results in CPSF73 binding comparable with fulllength Symplekin (Fig. 3A,B). These data indicate that while the N-terminal 271 amino
acids of Symplekin are not required for CCC formation, these residues inhibit CPSF73
binding to the C-terminal end of Symplekin. The C-terminal 85 amino acids of Symplekin
enhance CPSF73 binding. Also, CPSF73(466– 552) maintains binding to CPSF100 but not
Symplekin, while CPSF73(466–684) IPs both CPSF100 and Symplekin (Fig. 3E,F). These
data support a model in which CPSF73 amino acids 466–552 interact with CPSF100 while
CPSF73 amino acids 466–684 are required for binding Symplekin.
The in vivo binding data presented here, considered with previous X-ray crystal
structure and bioinformatic analyses, indicate dramatic regional separation of functions
within CPSF73, CPSF100, and Symplekin. Our N-terminal CPSF73(1–465) mutant
encompasses the entire active site (Fig. 2A; Mandel et al. 2006), but these amino acids
are not required for CCC formation (Fig. 3E,F). The region of CPSF73 responsible for
endonuclease activity is completely distinct from the residues required for CCC formation.
We hypothesize that use of an independent domain for CCC formation allows substrate
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RNA access to the CPSF73 active site. Additionally, CPSF100 amino acids 648–756 are
required for CCC formation (Fig. 3C,D). None of the residues comprising the β-CASP or the
metallo-β-lactamase domain are contained within this region of CPSF100. The first 271
amino ac- ids of Symplekin comprise a HEAT domain that can interact with and stimulate
activity of RNAPII CTD phosphatase Ssu72 (Xiang et al. 2010). This function of Symplekin
is con- fined to the N-terminal region while C-terminal residues are required for CCC
formation. Data presented here support a model in which each CPSF73, CPSF100, and
Symplekin domain has a discreet function related to either mRNA 3ʹ end processing or
CCC formation.
Poly(A) sites downstream from the H2A 3ʹ end processing site are used inefficiently when
the number of functional CCCs is low

In Drosophila, histone mRNAs are cotranscriptionally processed by the CCC
followed by RNAPII termination (Fig. 6A; Sullivan et al. 2009). These events require SLBP
binding to the SL, U7 snRNP interaction with the HDE and are coordinated by FLASH
(Sabath et al. 2013). Interaction of the CCC with the RNAPII CTD may not be direct, but
instead mediated by an additional protein(s). For instance, Ssu72 links Symplekin to the
RNAPII CTD in yeast and humans (Xiang et al. 2010). Under normal conditions, RNAPII
pauses ∼35 nt downstream from the histone mRNA 3ʹ end processing site (Adamson and
Price 2003). Presumably, this pause facilitates recruitment of all trans factors and allows
for correct alignment of the RNAPII associated CCC to the cleavage site. Processing is
followed by transcription termination. These events result in a proper 3ʹ processing of
histone mRNAs (Fig. 6A).

Michalski, Daniel, UMSL107
Previous data show that when CCC components CPSF73, CPSF100, or Symplekin
are RNAi-depleted, all three factors are knocked down, significantly reducing the total
number of CCCs and causing H2A 3ʹ end misprocessing (Wagner et al. 2007; Sullivan et al.
2009). A low concentration of CCCs results in primarily read through misprocessing as
cryptic poly(A) signals downstream from the proper H2A mRNA cleavage site are used less
often (Sullivan et al. 2009). This phenotype is also observed when CCCs do not properly
assemble as with CPSF100(525–647) and CPSF73 (466–552) (Fig. 3C–F). These mutants
cannot increase the concentration of functional CCCs, therefore, read through H2A
mRNAs dominate (Fig. 5B,C). When the concentration of CCCs is comparable with wild
type (Fig. 3E,F), but the CCCs do not contain functional CPSF73, read through H2A
misprocessing product is also prevalent (Fig. 5C,E). These data are in stark contrast to the
rescue of H2A misprocessing seen with CCCs containing the C-terminal 231 amino acids
of CPSF100 (Fig. 5B,E). The first 524 amino acids of CPSF100 are dispensable for
cotranscriptional H2A 3ʹ end processing.
These data support a model in which reducing the number of functional CCCs
prevents proper 3ʹ end processing and transcription termination resulting in H2A mRNAs
with an extended 3ʹ UTR (Fig. 6B). If a functional CCC can be recruited to the appropriate
cleavage site, proper H2A 3ʹ ends are formed as all other factors required for processing
are present. If a functional CCC is not available, cleavage and termination do not occur
and RNAPII keeps transcribing. Downstream cryptic poly(A) signals are not efficiently used
for H2A mRNA 3ʹ end processing when the concentration of functional CCCs is low
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although poly(A)-specific processing factors are recruited to these sites (Sullivan et al.
2009). The mechanistic basis for this observation remains an active area of investigation.
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Figure 3-6

FIGURE 6. Histone mRNA 3ʹ end processing models. (A) A model for cotranscriptional histone mRNA 3ʹ end processing
under normal conditions is shown. Following transcription of the cleavage site (black arrow) and HDE, RNAPII pauses
allowing recruitment and proper orientation of the CCC, SLBP, U7 snRNP, and FLASH to the cleavage site. This results in
H2A mRNA processing at the most proximal cleavage site (lightning bolt) and transcription termination. (B) A model for
cotranscriptional histone mRNA 3ʹ end processing under low CCC concentration conditions is shown. If a CCC can be
cotranscriptionally recruited to the cleavage site (black arrow), the H2A mRNA 3ʹ end will be properly processed
(lightning bolt). When no functional CCC can be recruited, RNAPII continues transcribing and use of downstream poly(A)
sites (white arrows) is inefficient resulting in read through (RT) H2A mRNAs. (C ) A model for H2A mRNA 3ʹ end
processing by CCCs containing Symplekin lacking the first 271 amino acids is shown. A high concentration of functional
CCCs containing N-terminally truncated Symplekin can use downstream poly(A) sites (white arrows) for H2A mRNA 3ʹ
end processing. We hypothesize that the first 271 amino acids of Symplekin mediate cotranscriptional histone mRNA
3ʹ end formation.
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CCCs lacking the first 271 amino acids of Symplekin use downstream poly(A) sites for H2A
mRNA 3ʹ end processing

Amino acids 272–1165 of Symplekin are sufficient to form functional CCCs (Fig.
3A,B). As these CCCs contain full- length endogenous CPSF73, we expected H2A mRNAs
in Dmel cells expressing this Symplekin mutant to be properly processed. Surprisingly,
almost 32% of the H2A mRNAs in these cells are misprocessed (Fig. 5D,E). While read
through H2A mRNA is the dominant misprocessed product upon CCC factor RNAidepletion, CCCs containing N-terminally truncated Symplekin can efficiently use
downstream poly(A) sites for H2A mRNA 3ʹ end processing (Fig. 5D,E). The amount of read
through product in samples containing these mutants is approximately the same (Fig.
5D,E). These data indicate that the ability to utilize downstream poly(A) sites for H2A
mRNA 3ʹ end processing is specific to the N-terminal 271 residues of Symplekin. The
efficiency of CCC formation (Fig. 3A,B) for each N-terminal Symplekin deletion mutant is
reflected in the total amount of H2A 3ʹ end misprocessing. CPSF73 is recruited more
efficiently to Symp(272– 1165) than to full-length Symplekin and we hypothesize that a
higher concentration of active CCCs causes increased use of downstream poly(A) signals.
As residues are deleted from the Symplekin C-terminus and less functional CCC are
formed, total H2A 3ʹ end misprocessing decreases and the read through H2A mRNAs
dominate (Fig. 5D,E).
Our evidence supports a model in which cotranscriptional histone mRNA 3ʹ end
processing is mediated by the N-terminal 271 amino acids of Symplekin (Fig. 6C). When
the number of functional CCCs is high, but Symplekin amino ac- ids 1–271 are absent,
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cryptic downstream poly(A) signals can be efficiently utilized for H2A mRNA 3ʹ end
processing. This is in contrast to read through products observed when the concentration
of functional CCCs is low but full-length Symplekin is present (Fig. 6B). Previous
experiments specify a role for the N-terminal region of Symplekin in cotranscriptional
polyadenylation. Amino acids 30–340 of human Symplekin were cocrystallized with
RNAPII CTD phosphatase Ssu72 and a RNAPII CTD peptide supporting strong interactions
between these proteins (Xiang et al. 2010). The human Symplekin N-terminal domain
inhibits transcription coupled polyadenylation in vitro (Xiang et al. 2010). Additionally, the
use of downstream poly(A) sites for H2A mRNA 3ʹ end processing observed for Nterminally truncated Symplekin containing CCCs is similar to the processing pattern of
H2A mRNAs when histone-specific processing factors SLBP, U7 snRNP, and FLASH are
RNAi-depleted (Lanzotti et al. 2002; Tatomer et al. 2014). SLBP, U7 snRNP, and FLASH are
hypothesized to be required for cotranscriptional 3ʹ end processing of histone mRNAs.
Taken together, these data best support two hypotheses. Either the first 271 amino acids
of Symplekin are required for interaction with histone-specific 3ʹ end processing factors
or they mediate interaction indirectly or directly with RNAPII. These ideas are being tested
in vivo using our Drosophila tissue culture system.
MATERIALS AND METHODS

All materials and methods were initially written by me and revised by Dr. Steiniger.
Gene cloning and plasmid construction

Full-length CPSF73, CPSF100, and Symplekin were PCR amplified from Drosophila
gene collection (DGC) clones (Open Biosystems) using specific primers. The amplified
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genes were directionally cloned into pENTR D-TOPO (Invitrogen) to create CPSF73,
CPSF100, and Symplekin::pENTRD-TOPO. Proper gene insertion was confirmed via
restriction digest and Sanger sequencing. CPSF73, CPSF100, and Symplekin::pENTRDTOPO were each re- combined with pAHW and pAWH destination vectors (Drosophila
Gateway vector collection, Carnegie Institution for Science) using Clonase II (Life
Technologies). Proper gene recombination was confirmed via restriction digest and
Sanger sequencing. Deletion mutants for each of the three CCC proteins were cloned and
recombined as described for their FL counterparts.
RNAi-resistant (RNAi-R) Symplekin, CPSF73, and CPSF100 were designed using an
online tool described in Schulz et al. (2009). This tool changes wobble bases within a
targeted area while also being sensitive to codon bias. A DNA fragment corresponding to
the ∼500 bp target region was synthesized as a GeneArt Strings DNA Fragment by Life
Technologies. Each RNAi-R GeneArt String and corresponding Symplekin, CPSF73, or
CPSF100::pENTRD-TOPO were digested with restriction enzymes and the RNAi-R
fragment was substituted for the wild-type piece to create RNAi-R Symplekin, CPSF73,
and CPSF100::pENTRD-TOPO. Ligation was confirmed via restriction digest and Sanger
sequencing. RNAi-R Symplekin, CPSF73, and CPSF100::pENTRD-TOPO were each
recombined with pAHW and pAWH destination vectors as described above. Proper recombination was again confirmed via restriction digest and Sanger sequencing.
Creation of stable Drosophila Dmel-2 tissue culture lines
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Full-length/mutant CCC factor::pAHW or full-length/mutant CCC factor::pAWH
were transfected into Drosophila Dmel-2 cells with Effectene Transfection Reagent
(Qiagen) according to the manufacturer’s protocol. The pCoBlast vector (Invitrogen)
containing a Blasticidin resistance gene was cotransfected to enable selection of
successfully transfected cells. Cells were grown in SF-900 II SFM (Gibco) and maintained
at 27°C under normal atmospheric condi- tions. Forty-eight hours post-transfection,
Blasticidin (25 μg/mL) was added to the media to select for stably transfected cells. Cells
were split and passaged into fresh selective media every 5 d to a con- centration of 1 ×
106/mL. Stable transfection was confirmed via Western blot with anti-HA antibody
(Covance).
RNAi, whole-cell lysate preparation, nuclear extract preparation and RNA isolation

RNAi was performed as described (Sullivan et al. 2009). On Day 5, the cells were
counted with a Nexcelom cell counter and harvested for analysis. To make whole-cell
lysates, 5 × 106 RNAi-depleted or control cells were lysed with RIPA buffer (50 mM Tris–
HCl (pH 8), 150 mM NaCl, 1% Nonidet P-40, 0.25% Na deoxycholate) plus 5 μL 100× Halt
Protease inhibitor (Thermo Scientific), and rotated at 4°C for 10 min and centrifuged for
15 min at 14,000 rpm to remove cellular debris. The supernatant was transferred to a
new tube and filtered through a 1 mL syringe with a 26 Gauge needle to shear the
chromatin. NEs were prepared as described (Sullivan et al. 2009) from 1 × 108 cells and
then flash frozen in liquid N2 and stored at −80°C. Whole-cell lysates and NEs were used
for immuno- precipitations (IPs) and protein expression analysis. Total RNA was extracted
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from RNAi-depleted or control cells with TRIzol Reagent (Sigma) as described previously
for use in S1 assays (Sullivan et al. 2009).
Antibodies

Monoclonal and polyclonal HA antibodies (Cat #s MMS-101R and PRB-101C,
respectively, Covance) were used for both IP (3 μL) and WB (1:1000). Anti-CPSF73, antiSymplekin, and anti-CPSF100 antibodies were described previously (Sullivan et al. 2009;
Yang et al. 2009). For WB, antibodies were used at 1:1000.
Immunoprecipitation and S1 nuclease protection assay

IP of HA-tagged proteins were performed as described (Sullivan et al. 2009). S1
nuclease protection assay was also performed as de- scribed (Sullivan et al. 2009).
IP quantitation

Blots were scanned at 600 PPI and analyzed using ImageJ software. Intensity of
protein bands representing IP or co-IP were determined and compared with the intensity
of the corresponding input band (representing 5% of the sample). The ratio of IP or co-IP
intensity to input intensity was multiplied by 5 to determine the percentage of total
protein immunoprecipitated from the sample.
S1 quantification

Two independent experiments were quantitated for each S1 experiment. Dried
6% Urea/TBE sample gels were placed on phosphoscreens overnight. Phosphoscreens
were scanned using a STORM Scanner and images were saved as TIFF files. The TIFF files

Michalski, Daniel, UMSL115
were imported into ImageJ software and subsequently analyzed. Peak areas were
determined for bands corresponding to RT, misprocessed and properly processed H2A
mRNAs. The sum total of all peaks in each lane was then determined and the area for
each peak (band) was divided by the sum total of peaks in that lane to give a percentage.
The percentages were averaged and the standard deviation calculated for all products in
each sample.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FIGURE 1

Figure 1. RNAi-resistant (RNAi-R) CCC deletion mutants are expressed during simultaneous knockdown of
corresponding endogenous proteins. RNAi-R CCC deletion mutants were constructed as described in Figure 4 or were
RNAi-R because the dsRNA targeted region was not contained in the deletion (Figure 2). HA-tagged, N- and C-terminal
RNAi-R deletion mutants of (A) Symplekin (B) CPSF100 and (C) CPSF73 were expressed in Dmel-2 cells simultaneously
RNAi-depleted of the corresponding endogenous protein. Depletion of endogenous protein in each mutant cell line was
compared to no dsRNA and non-specific (LacZ) dsRNA controls.
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SUPPLEMENTAL FIGURE 2

Figure 2. Symplekin and CPSF73 deletion mutants do not act dominantly in the presence of wild type, full length
endogenous CCC components. HA-tagged CPSF73 and Symplekin deletion mutants were expressed in Dmel-2 cells in
the absence of RNAi-depletion of endogenous CCC components. H2A 3’ ends were assessed by S1 assay as in Figure 5.
Gels are labeled as in Figures 5B-5D. Samples having CPSF73 (A) and Symplekin (B) and mutants showed only properly
processed H2A mRNA.
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CHAPTER 4: Discussion and Future Directions
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Pre-mRNA 3ʹ end processing is an essential step in mRNA maturation. The 3ʹ ends
of all metazoan mRNAs are cleaved by the core cleavage complex (CCC) consisting of
CPSF73, CPSF100, and Symplekin (Sullivan et al. 2009). Interactions in this important
complex had not been investigated, and the relationships between protein domains in
the CCC and their function in cotranscriptional histone mRNA 3ʹ-end processing had not
yet been characterized. Here, we used a Dmel-2 tissue culture system that enabled us to
determine that the C- terminal ∼200 amino acids of CPSF73 and CPSF100 and amino acids
272–1080 of Symplekin are sufficient for CCC formation. Additionally, in vivo assessment
of mutant CCC activity revealed that the N-terminal 524 amino acids of CPSF100 are not
required for formation of CCCs that properly process histone mRNAs. Lastly, CCCs
containing C-terminal Symplekin (272-1165) can use poly(A) signals downstream from the
proper cleavage site for 3’-end processing. This is a phenotype also observed when
histone-specific processing factors are RNAi-depleted but in contrast to the read through
product normally produced when CCC components are knocked down. These data
support a model in which the N-terminal 271 amino acids of Symplekin facilitate
cotranscriptional 3’-end processing of histone mRNAs.
I took a novel in vivo approach to investigate both CCC interactions and mutant
CCC histone mRNA 3ʹ-end processing. To identify important CCC factor binding regions,
tagged CCC factor mutants were first stably expressed in Dmel-2 cells. These proteins
were then immunoprecipitated and co-IP of endogenous CCC-binding partners were
identified. This approach was validated using full-length, wild-type tagged CCC factors for
IP and ensuring co-IP of endogenous CCC components. Unlike several previous studies
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investigating the interactions within multiprotein complexes involved in RNA processing,
mixed CCCs having both exogenous and endogenous components did not require RNAidepletion of endogenous factors in order to observe binding patterns (Chen et al. 2013;
Lyons et al. 2014).
Analysis of mutant CCC activity in this system necessitated an additional
modification. Previous data indicate that misprocessed histone mRNAs are a small
percentage of total histone mRNA in Dmel-2 cells RNAi-depleted of CCC components
(Sullivan et al. 2009). Therefore, we hypothesized that misprocessed histone mRNA
resulting from mutant CCC activity in our system would not be detected in the presence
of functional wild-type CCCs. To alleviate this problem, I constructed and stably expressed
RNAi-resistant CCC mutants simultaneously with effective RNAi-depletion of the
corresponding endogenous CCC component. This approach ensured we were observing
activity of mutant CCC factors alone. We must, however, address the fact that RNAimediated protein KD does not fully prevent expression of the targeted protein. Thus, even
in cells treated with dsRNA intended to knock-down a targeted protein there is likely
some residual amount of wild-type protein being expressed. This then would allow WT
CCCs to form and properly cleave histone mRNAs. This explains why even in the presence
of RNAi the vast majority of histone pre-mRNAs are processed correctly. Despite the fact
that RNAi is not 100% effective, this approach allowed the phenotypes associated with
each mutant CCC to be observed via the use of an S1 nuclease assay. Expression of tagged
full-length, wild-type CCC components rescued histone mRNA 3ʹ-end processing when the
corresponding endogenous component was RNAi-depleted, indicating that mixed CCCs
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are also functional. Thus, this novel research has provided a proof of concept Dmel-2 cell
culture system in which an endogenous cellular protein, known to interact and bind to
another protein in a complex, can be replaced with an exogenously expressed mutated
version in order to test for functional consequences of whatever cellular process it is
involved in. Additionally, this system can be employed to further investigate interactions
within the CCC using CPSF73, CPSF100, and Symplekin point mutants, or to test
interactions between the CCC and other cleavage and polyadenylation processing factors.
This system could also be used to look at how other protein factors required for
cotranscriptional histone mRNA 3ʹ-end processing contribute to the processing event.
The C-termini of CPSF73, CPSF100, and Symplekin are sufficient for CCC formation:
Significance of findings

Previous to this study, little was known about CCC interactions in vivo. The threedimensional structure of the Drosophila mRNA core cleavage complex had been
characterized based on X-ray crystallography of the N-terminal ∼400 amino acids of both
human CPSF73 and yeast CPSF100 Fig 1-O (Mandel et al. 2006; (Kennedy et al. 2009;
Xiang et al. 2010, 2012), and the N-terminal ∼300 amino acids of Drosophila and human
Symplekin. These structures were important for characterizing CCC binding interactions
as they included the specific residues comprising the CPSF73 active site and a N- terminal
Symplekin HEAT domain, My hypothesis is that the Symplekin HEAT domain directly
contacts the RNAPII CTD phosphatase Ssu72. These crystal structures do not, however,
incorporate the C-terminal regions of CPSF73, CPSF100, and Symplekin. Additionally,
previous bioinformatics, yeast-two hybrid and pull-down analyses have led to hypotheses
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that the C-termini of CPSF100, CPSF73, and Symplekin interact (Jenny et al. 1996; Kyburz
et al. 2003; Dominski et al. 2005b; Zhelkovsky et al. 2006; Mandel et al. 2008; Ghazy et al.
2009), but these studies did not include all three CCC components together in a complex
of three, instead focusing on only two factors. The experiments described here are the
first systematic, in vivo approach to defining simultaneous CPSF73, CPSF100, and
Symplekin binding interactions within the CCC. We provide evidence that amino acids
272–1080 of Symplekin, amino acids 466–684 of CPSF73 and amino acids 525– 756 of
CPSF100 are sufficient for CCC formation. While our data are generally consistent with
previous hypotheses and observations, our experiments reveal the following novel
insights. Symplekin amino acids 272–1165 co- IP more CPSF73 than full-length Symplekin,
yet removing 85 additional C-terminal amino acids (Symp(272–1080)) results in CPSF73
binding comparable with full-length Symplekin. These data indicate that while the Nterminal 271 amino acids of Symplekin are not required for CCC formation, these residues
may play a role to inhibit CPSF73 binding to the C-terminal end of Symplekin. The Cterminal 85 amino acids of Symplekin appear to enhance CPSF73 binding. Also,
CPSF73(466– 552) maintains binding to CPSF100 but it does not bind Symplekin, while
CPSF73(466–684) IPs both CPSF100 and Symplekin. These data support a model in which
CPSF73 amino acids 466–552 interact with CPSF100 while CPSF73 amino acids 466–684
are required for binding Symplekin. The in vivo binding data presented here, considered
with previous X-ray crystal structure and bioinformatic analyses, indicate dramatic
regional separation of functions within CPSF73, CPSF100, and Symplekin based on
primary and secondary protein structure. Our N-terminal CPSF73(1–465) mutant
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encompasses the entire active site (Mandel et al. 2006), but these amino acids are not
required for CCC formation. The region of CPSF73 responsible for endonuclease activity
is completely distinct from the residues required for CCC formation. We hypothesize that
use of an independent domain for CCC formation allows substrate RNA access to the
CPSF73 active site. Additionally, CPSF100 amino acids 648–756 are required for CCC
formation, yet these C-terminal residues are distinct from the residues comprising the βCASP or the metallo-β-lactamase domain. The two domains are contained within the Nterminal ~2/3 of the protein.. X-ray crystal structure data reveals the first 271 amino acids
of Symplekin comprise a HEAT domain, which has since been shown to be capable of
interacting with and stimulating activity of the RNAPII CTD phosphatase Ssu72 (Xiang et
al. 2010). It appears this function of Symplekin is confined to the N-terminal region while
specific C-terminal residues are required for CCC formation. The data presented here
support a model in which known domains of each CPSF73, CPSF100, and Symplekin have
a distinct and discreet function related to either mRNA 3ʹ end processing or CCC
formation.

CCCs lacking the N-terminal 271 amino acids of Symplekin use cryptic poly(A) sites
downstream of the proper H2A mRNA 3’ end processing site due to cotranscriptional
processing defects

Amino acids 272–1165 of Symplekin are sufficient for forming functional CCCs. As
these CCCs contain full-length endogenous CPSF73, we expected H2A mRNAs in Dmel
cells expressing this Symplekin mutant to be properly processed. Surprisingly, almost 32%
of the H2A mRNAs in these cells are misprocessed. While read through (RT) H2A mRNA is
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the dominant misprocessed product upon CCC factor RNAi-depletion, CCCs containing Nterminally truncated Symplekin (lacks the first 271 a.a. of the protein) can efficiently use
downstream poly(A) sites for H2A mRNA 3ʹ end processing. The amount of read through
product in samples containing these mutants is approximately the same. These data
indicate that the ability to utilize downstream poly(A) sites for H2A mRNA 3ʹ-end
processing is specific to (and a primary function of) the N-terminal 271 residues of
Symplekin. The efficiency of CCC formation for each N-terminal Symplekin deletion
mutant is reflected in the total amount of H2A 3ʹ-end misprocessing. According to our coIP data, CPSF73 gets recruited more efficiently to Symp(272– 1165) than to full-length
Symplekin, possibly due to missing secondary structures creating some degree of steric
hindrance. Thus we hypothesize that a higher cellular concentration of active CCCs,
possessing a functioning CPFS73 but an N-terminally truncated Symplekin, caused the
increased use of downstream cryptic poly(A) signals revealed by the S1 nuclease assays.
As residues are deleted from the Symplekin C-terminus, which is the region required for
binding and CCC complex formation, presumably less and less functional CCCs are formed
and so total H2A 3ʹ-end misprocessing decreases and the read through H2A mRNAs, which
lack any form of processing, dominate.
Our experimental evidence supports a model in which cotranscriptional histone
mRNA 3ʹ end processing is mediated by the N-terminal 271 amino acids of Symplekin.
When the number of functional CCCs (possessing a full-length CPSF73) is high but
Symplekin is lacking the first 271 amino acids, cryptic downstream poly(A) signals
suddenly can be efficiently utilized for H2A mRNA 3ʹ-end processing. This is in contrast to
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read through products observed when the concentration of functional CCCs is low but
full-length Symplekin is present. Previous experiments specify a role for the N-terminal
region of Symplekin in cotranscriptional cleavage and polyadenylation. Experiments have
shown that amino acids 30–340 of human Symplekin were co-crystallized with RNAPII CTD
phosphatase Ssu72 and a RNAPII CTD peptide, lending strong support to the notion that
Symplekin does indeed interact with the RNAPII CTD. This interaction is possibly quite
transient due to the nature of Ssu72 phosphatase (Xiang et al. 2010). It must be noted,
however, that the N-terminal domain of human Symplekin was shown to inhibit
transcription coupled polyadenylation in vitro (Xiang et al. 2010). The key to addressing
this possible contradiction to the idea I am proposing is based on the fact that all of the
experiments from the study were done in vitro, not in vivo. Additional evidence
supporting the co-transcriptional role for the N-terminal of Symplekin is that use of
downstream poly(A) sites for H2A mRNA 3ʹ-end processing observed for N-terminally
truncated Symplekin containing CCCs is similar to the processing pattern of H2A mRNAs
when histone-specific processing factors SLBP, the U7 snRNP, and FLASH are RNAidepleted (Lanzotti et al. 2002; Tatomer et al. 2014). Protein factors SLBP, U7 snRNP, and
FLASH are hypothesized to be required for cotranscriptional 3’-end processing of histone
mRNAs. Taken together, these data best support the following hypothesis: The first 271
amino acids of Symplekin are required for CCC interaction with the RNAPII CTD (either
directly or indirectly), and this interaction subsequently promotes CCC interaction with
histone-specific 3’- end processing factors. This combination of interactions promotes
proper cleavage of histone pre-mRNAs into mature histone mRNAs.
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As a recap, regulation of gene expression is vital for proper cellular differentiation,
cellular proliferation, and organismal development. At the post-transcriptional level this
regulation involves proper processing of pre-mRNAs. There exist two types of cellular premRNAs: histone pre-mRNAs and poly(A) pre-mRNAs. Both types of pre-mRNAs are
processed by numerous large multi-protein complexes as well as individual RNA binding
proteins. The core cleavage complex is comprised of CPSF73, CPSF100, and Symplekin, a
trio of pre-mRNA processing proteins that have been shown to be dependent on one
another for stabilization. This complex is required for the 3’-end processing of all
metazoan pre-mRNAs, thus, identifying binding interactions within this complex and
characterizing its functionality on histone and poly(A) mRNA processing is important so
that we have a correct map detailing how proper pre-mRNA are processing at the 3’-end.
This work was completed in the model organism Drosophila melanogaster (a.k.a.
the fruit fly), which utilized a user friendly embryonic tissue culture cell line known as S2
or Dmel-2 cells intended for research purposes. Working in this model system provided
ease of study and system manipulation for characterizing the core cleavage complex. The
work performed and the results obtained from using this model system are translational,
in that, this complex of proteins has homologs in human cells. Thus, should the need arise
scientists could examine this complex in human cell lines, utilizing the results of this study
for their needs.
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